This is an Accepted Manuscript of an article published by Taylor & Francis in Disability and rehabilitationon on 05 Sep 2021 (published online), available at: http://www.tandfonline.com/10.1080/09638288.2021.1970248

# Effect of ankle-foot orthoses on functional outcome measurements in individuals with stroke: A systematic review and meta-analysis

Aliyeh Daryabor<sup>a,\*</sup>, Toshiki Kobayashi<sup>b</sup>, Sumiko Yamamoto<sup>c</sup>, Samuel M. Lyons<sup>d</sup>, Michael Orendurff<sup>e</sup>, Alireza Akbarzadeh Baghban<sup>f</sup>

a. PhD, Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

b. PhD, Department of Biomedical Engineering, Faculty of Engineering, Hong Kong Polytechnic University, Hong Kong, China

c. PhD, International University of Health and Welfare, Japan, Tokyo

d: Motion Analysis and Sports Performance Lab, Department of Orthopedic Sports Medicine, Lucile Packard Children's Hospital, Stanford.

e. PhD, Director, Oregon Biomechanics Institute, Ashland, Oregon USA

f. PhD, Proteomics Research Center, Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

# \*Corresponding author: Aliyeh Daryabor (ORCID: 0000-0002-0652-6025)

1. PHD, Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Damavand street, Emam Hossein squre, Tehran, 1616913111, Iran.

Email: r\_daryabor@yahoo.com, aliyehdaryabor@gmail.com

# Acknowledgements

The authors would like to thank Dr. Corien Nikamp for providing us additional data for

the meta-analysis.

# **Author contributions**

A.D. and T.K. drafted the study protocol, developed the search strategy, and wrote the initial draft. S.Y, SM.L, M.O, and A.A. revised the content. All authors were involved for revising, drafting the final review, and approving the final manuscript. A.D. conducted all analyses and takes responsibility for the precision of findings.

# **Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

# Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article

# Abstract:

**Purpose:** To determine and compare the effect of ankle-foot orthosis (AFOs) types on functional outcome measurements in individuals with (sub)acute or chronic stroke impairments.

**Methods:** PubMed, Web of Knowledge, Embase, Scopus, ProQuest, and Cochrane were searched from inception until September-2020. Methodological quality assessment of 30 studies was conducted based on the Downs and Black checklist. Functional indices were pooled according to their standardized mean difference (SMD) and 95% confidence intervals (CI) in a random-effect model. A narrative analysis was performed where data pooling was not feasible.

**Results:** Overall pooled results indicated improvements in favor of AFOs versus without for the Berg Balance Scale (SMD:0.54, CI:0.19 to 0.88), timed-up and go test (SMD:-0.45, CI:-0.67 to -0.24), Functional Ambulatory Categories (SMD:1.72, CI:1.25 to 2.19), 6-Minute Walking Test (SMD:0.91, CI:0.53 to 1.28), Timed Up-Stairs (SMD:-0.35, CI:-0.64 to 0.05), and Motricity Index (SMD:0.65, CI:0.38 to 0.92). Heterogeneity was non-significant for all outcomes ( $I^2 < 50\%$ , p>0.05) except the Berg Balance Scale and Functional Ambulatory Categories. Additionally, there was not sufficient evidence to determine effectiveness of specific orthotic designs over others.

**Conclusions:** An AFO can improve ambulatory function in stroke survivors. Future studies should explore long-term effects of rehabilitation using AFOs and compare differences in orthotic designs.

#### Word count:200

Keywords: Orthosis, Cerebrovascular Accident, Walking, Mobility, Function, Gait

**Abbreviations:** 6MWT: 6-minute walking test; AFO: ankle-foot orthosis; AFO-PS: hinged plastic or metal AFO with plantarflexion stop and dorsiflexion free; BBS: berg balance scale; FAC: functional ambulatory categories; FIM: functional independence measure; FRT: functional

reach test; PLS-AFO: posterior leaf spring AFO; mEFAP: modified Emory Functional Ambulation Profile; TDS: timed down stairs; TUG: timed-up and go test; TUS: timed up stairs

#### **1. Introduction**

Strokes are a common neurological impairment resulting in reduced functional mobility due to postural and dynamic instability, slow gait velocity, low self-efficacy, and decreased independence during activities of daily living (ADLs) [1,2]. The improvements of gait stability and physical function are primary goals of rehabilitation following a stroke [3,4]. Ankle-foot orthoses are frequently prescribed to improve ambulatory function and efficiency during stroke rehabilitation[5].

A wide variety of mobility tests exist to evaluate individuals post stroke[6,7]. Some highly technical tests, such as computerized gait analysis can provide detailed information about gait kinematics and kinetics that can be used to guide specific treatment choices, including orthotic design characteristics[8,9]. Metabolic testing is another mobility test that provides detailed information about the energy cost associated with ambulation post stroke, and can provide information about the effectiveness of a specific intervention[10,11]. However, both of these methods are focused primarily on gait biomechanics, and although implying the potential to ambulate effectively, do not directly quantify an individual's ambulatory function and independent mobility tests have been developed that can be more rapidly applied in the clinic setting, and if these tests have acceptable reliability and validity, can be used to guide treatment decisions, and evaluate treatment outcomes. Clinical measurements may have higher ecological validity for functional outcome assessments because they are designed to assess the performance of activities that better reflect ADLs or have more real-world relevance in contrast to the straight ahead single

speed walking most often used in the computerized gait analysis [6,11]. Moreover, clinical outcome measurements are designed to evaluate functional ability by mimicking real world tasks, such as sit-to-stand up and reaching out, and they could be used to evaluate the potential for improvement with rehabilitation interventions including specific AFO prescriptions and gait retraining [12]. Hence, understanding clinical outcome measurements during ambulation is important for evaluating the general effects of AFOs on patients' functional performance and activities in their daily life.

Previous systematic reviews have evaluated AFO performance using different types of mobility tests [8-10,13,14]. However, only one review addressed the effects of AFOs on selected functional outcomes evaluated by clinical tests in individuals with a history of a stroke [13]. The previous review was completed in 2013 and focused more on computerized laboratory tests. Moreover, the analysis did not compare different designs of AFOs in individuals who had suffered a stroke. Thus, the aim of this study was to systematically review the evidence for the impact of AFOs and their designs on clinical outcome measurements in individuals with poststroke hemiplegia.

## 2. Methods

#### 2.1. Search strategy

The protocol of present systematic review was already registered in the PROSPERO database (registration no. CRD42020179330). The search strategy was conducted by the population intervention comparison outcome (PICO) method. We identified all relevant papers published from inception until September 2020. After paper identification, the process followed the PRISMA guideline (Fig. 1). The following databases were searched: PubMed, ISI web of

6

knowledge, Embase, Scopus, ProQuest, and Cochrane. First, a search strategy for PubMed was established, which was then adapted for other databases (Supplemental Appendix 1). The search procedure was performed by an investigator (A.D.). After removing duplicates by Endnote X7 software, the titles, and abstracts were independently reviewed for eligibility by two researchers (A.D. and T.K.); the full texts of the papers were then acquired. Two investigators (A.D. and T.K.) initiated the paper selection process based on the eligibility criteria. Any disagreement in selection procedure was resolved by discussion between the two investigators and if needed, consultation of the third investigator (S.Y.) was also conducted.

## 2.2. Study types

The review consisted of clinical trials (including paired sample, parallel or crossover designs, unblinded or blinded) without any language limitation, which compared (1) outcomes with and without an AFO (barefoot or with shoes) (Intervention); (2) outcomes between different types or designs of AFOs (Intervention); (3) outcomes of patients with hemiplegia secondary to stroke (chronic or (sub)acute) (Population); and (4) applied outcome measures of functional tests in a clinical setting (Outcome measure). Studies that used other orthotic devices, such as powered orthoses and air-pressure splints, were excluded since those are not necessarily suitable for daily use. Thus, only passive orthoses were included. Passive AFOs are generally grouped into two types: non-articulated and articulated orthoses. The passive non-articulated AFOs include different designs, such as a posterior leaf spring AFO (PLS-AFO), rigid AFO, carbon fiber AFO, dynamic supramalleolar AFO, and an anterior AFO [15]. The passive articulated AFOs have a variety of joint designs, which stop or resist plantarflexion and/or dorsiflexion movement. These AFOs include options of custom plastic or metal AFOs with plantarflexion stop, dorsiflexion free, and plantarflexion resistance designs, as well as a Chignon AFO (an

double-stopped custom-made AFO with posterior joint made out of molded carbon fiber) [15]. We also excluded the knee-ankle-foot orthoses (KAFOs) studies because the mobility subscales of KAFO users are significantly lower than that of AFO users.

#### 2.3. Assessment of methodologic quality

The methodological quality assessment of the included studies was conducted based on the Downs and Black checklist, which consisted of the sections of reporting, external validity, bias, confounding, and power [16]. For the present review, we modified this checklist to 17 items, because giving a score to some items was not possible due to the non-conformity of the items in the included papers. Each answered question received "unable to determine" (score 0), "no" (score 0), or "yes" (score 1). Table 1 lists the Downs and Black scales for the selected papers.

#### 2.4. Data extraction

Two investigators (A.D. and T.K.) carried out the data extraction. The following data were extracted from the selected trials indicated in Table 2: first author's name with publication year, trial design, sample size, population recruited (age, gender, time from stroke), stroke phase, inclusion and exclusion criteria, intervention delivered, adaptation time with an AFO, outcomes measured, walking velocity, and quality status. If required, we contacted the authors for clarification or missing data.

#### 2.5. Statistical analysis

Regarding the meta-analysis (quantitative analysis), the mean and standard deviation (SD) of parameters were extracted. If mean and SD were not reported, we

contacted the authors by email to obtain their unpublished data. When we did not receive a response from the authors, we followed the methods suggested by Wan et al. to calculate mean and SD based on median and interquartile range (IQR) [17]. Where possible, the effect size across the studies was calculated by standardized mean difference (SMD; Cohen's d) and 95% confidence intervals (CI) using a random-effects model. For a better interpretation of pooled analyses, SMD of 0.2, 0.5, 0.8, and >0.8 were chosen to correspond to small, medium, large, and very large change, respectively.

We represented the findings for every comparison in forest plots. When studies reported the effects of two different AFOs, the data from both orthoses were included in the analysis. The heterogeneity was evaluated using I-square ( $I^2$ ). The degree of heterogeneity was categorized into low, medium, and high based on the I<sup>2</sup>-values of < 25%, 25%–50%, and 50%–100%, respectively. If the number of papers for each comparison was more than 10, a funnel plot was planned in order to evaluate the publication bias [18]. In case the number of papers was less than 10, Begg's and Egger's tests were used to evaluate publication bias [19,20]. Subgroup analyses were conducted for time from stroke ("<6 months," "> 6 months," or "mixed"), AFO type (non-articulated or articulated), follow-up period (immediate, <3 months, > 3 months), walking speed (without orthosis: household, <0.4 m/s; limited community, 0.4-0.8 m/s; community, >0.8 m/s) [21], and methodological quality of the studies (poor, fair, and good). A narrative analysis was performed where data pooling was not feasible (<4 studies). Stata software 11.0 (Stata-Corp LP, USA) was used for all analyses.

#### 2.6. Outcome measures

Based on the literature selected for analysis, independence of walking was assessed using the Functional Ambulation Categories (FAC); walking ability (endurance) with the 6-Minute Walking Test (6MWT); functional mobility with the Timed Up and Go test (TUG), stairs tests (Timed Going Up (TUS) or Down (TDS)), and modified Emory functional ambulation profile (mEFAP). Balance was assessed with Berg Balance Scale (BBS) and Functional Reach Test (FRT). In every study selected for the analysis, the tests related to walking were performed at the participant's self-selected gait velocity. Other outcome measures used for the analysis included Functional Independence Measure (FIM) subscores related to mobility and locomotion (stair-climbing and walk/wheelchair); plantarflexor spasticity, evaluated by the Modified Ashworth scale; the Motricity Index, which assesses isometric contraction and selective muscle control; and the Barthel Index and Rivermead Mobility Index, which evaluate mobility during ADLs. Since a recent systematic review addressed the effect of AFOs on walking speed [22], we did not include walking speed measured by clinical tests for the present review. We did, however, consider it as a factor of sub-group analysis.

## 3. Results

#### 3.1. Description of studies

In total, 30 studies (29 articles and 1 thesis) involving 669 participants were included for final evaluation (Figure 1). A list of excluded studies with their exclusion reason has been presented in Supplemental Appendix 2. The quality status of the studies had a scientific rigor of 11 (medium or fair) out of 17 and ranged from 8 (low or poor) to 13 (high or good) (Tables 1 and 2). All studies failed in the items which evaluated the adequacy of population representation, and the blinding of patients or therapists. A non-randomized, one-group clinical design (quasiexperimental) was included in 10 papers in which functional tests without an AFO were defined as the control trials without a randomization for the order of tests [23-32]. A randomized, onegroup clinical design (quasi-experimental) was included in 13 papers in which functional tests without an AFO were the control trial with a randomization for the order of tests [33-45]. A randomized, parallel-group controlled design (RCT) was included in six papers in which one group of the patients used an AFO and the control group was evaluated with only shoes or other AFOs [46-51]. One study included a non-randomized parallel-group trial in which participants were not assigned randomly to two groups [52]. Seven papers evaluated the immediate effect of an AFO (without adaptation)[27,29,33,36,40,43,49], and other studies assessed the short-term (< 3 months) [24,26,28,30,31,35,37,38,40-42,44,48,50,52] or long-time effects (> 3 months) [23,34,39,46,47,50,51] of an orthosis. Most studies had small sample sizes (4-61 subjects), and a sample size calculation (power) was reported in five studies [36,42,45,46,49]. Most studies recruited participants with chronic impairments post stroke (>6 months) that did not undergo rehabilitative care (rehabilitative care refers to inpatient or non-hospitalized patients who are undergoing rehabilitation programs in hospitals or rehabilitation centers), except one [45] which recruited patients in this phase with gait training using an AFO. Other studies involved individuals in the early subacute (7 days to 3 months) and late subacute (<6 months) stages who were undergoing rehabilitative care (8 papers) [25,36,42-44,47,48,50]. Two papers did not state whether subjects were receiving rehabilitative care or were not in the subacute phase [33,43]. Three studies evaluated the mixed group of subacute and chronic hemiparetic patients [26,35,38], and two of them recruited patients with rehabilitative care [26,35]. Most papers utilized a non-articulated AFO for all participants, while seven studies used an articulated AFO

[24,25,27,35,40,42,50]. Five studies did not distinguish between articulated orthoses and nonarticulated orthoses (mixed group) [29,31,34,37,39].

### 3.2. Comparison of AFO versus without AFO

The results of Berg Balance Scale (BBS), Timed Up and Go test (TUG), Functional Ambulation Categories (FAC), 6-minute walking test (6MWT), Timed Up Stairs (TUS) and Motricity Index were analyzed quantitatively by a meta-analysis, while the results of Timed Down Stairs (TDS), Functional Reach Test (FRT), Modified Ashworth Scale, Functional Independence Measure (FIM), the modified Emory Functional Ambulation Profile (mEFAP), Barthel Index, and Rivermead Mobility Index were analyzed qualitatively by a narrative analysis.

#### 3.2.1. Results of quantitative analyses

**Berg Balance Scale (BBS):** This test is utilized to determine static and dynamic balance abilities using 14 list items. Each of the 14 assessment items of BBS ranges from 0 to 4, with 0 representing the lowest level of function and 4 the highest level of function. The effect of AFOs on BBS was reported in 11 trials. Overall pooled results were reported in Figure 2 (a). Pooled SMD demonstrated a moderate and significant improvement (SMD: 0.54, CI: 0.19 to 0.88) in favor of orthotic intervention compared with no orthosis by combining all trials. However, statistical heterogeneity was detected to be high (I<sup>2</sup>: 72.9%). Subgroup analyses based on stroke phase (Supplemental Figure 1(a)), adaptation time (Supplemental Figure 1(b)), study quality (Supplemental Figure 1(c)), and walking speed (Supplemental Figure 1(d)) were also presented. For AFO type, subgroup analysis was not applicable because the subgroups contained only a single study that used either an articulated orthosis or both non-articulated and articulated orthoses (mixed group).

**Timed Up and Go test (TUG):** This test is an assessment of person's mobility in which the time taken by an individual to stand up from a chair, walk 3 meters, turn, walk back, and sit down again is measured. Fifteen trials compared this mobility test with and without an AFO. Overall pooled SMD (Figure 2 (b)) demonstrated a moderate and significant difference (SMD:-0.45, CI:-0.67 to -0.24) between walking with and without an orthosis for the TUG test with a low level of statistical heterogeneity (I<sup>2</sup>: 21.7%). Subgroup analyses based on stroke phase (Supplemental Figure 2(a)), orthosis type (Supplemental Figure 2(b)) adaptation time (Supplemental Figure 2(c)), study quality (Supplemental Figure 2(d)), and walking speed (Supplemental Figure 2(e)) were also presented.

**Functional Ambulation Categories (FAC):** The FAC performance is categorized from 0 (needing support from 2 people) to 5 (can walk anywhere without supervision). We excluded one study for meta-analysis because IQR for FAC had not been reported, and we did not receive any responses from authors by email [51]. Fourteen trials compared this function with and without an orthotic intervention. Pooled results of an all trials combination identified a rate of 1.72 (95% CI 1.25 – 2.19) with a significant improvement using an AFO compared to without one (Figure 3 (a)). However, a significant heterogeneity was found (I<sup>2</sup>: 78.0%). Subgroup analyses based on stroke phase (Supplemental Figure 3(a)), orthosis type (Supplemental Figure 3(b)) adaptation time (Supplemental Figure 3(c)), and study quality (Supplemental Figure 3(d)) were also presented. For walking speed, subgroup analysis was not applicable.

**6-Minute Walking Test (6MWT):** We excluded one study for meta-analysis because SD value for 6MWT had not been reported, and we did not receive any responses from authors by email[26]. Thus, the effect of AFOs on the test performance was reported in seven trials. Pooled SMD demonstrated a large to very large and significant improvement (SMD: 0.91, CI:

0.53 to 1.28) in favor of orthotic intervention compared with no orthosis (Figure 3 (b)). The statistical heterogeneity was moderate ( $I^2$ : 34.4 %). Subgroup analyses based on stroke phase (Supplemental Figure 4(a)), adaptation time (Supplemental Figure 4(a)), study quality (Supplemental Figure 4(a)), and walking speed (Supplemental Figure 4(a)) were also presented. For orthosis type, subgroup analysis was not applicable because all trials included a non-articulated orthosis.

**Timed Up-Stairs (TUS):** Subjects were timed going up 10 steps, 5 steps in the mEFAP, and 7 steps in Ashburn test. Eight trials compared the performance of the test with and without an AFO. Pooled results of an all trials combination showed a low to moderate improvement (SMD:-0.35, CI:-0.64 to 0.05) and low heterogeneity (I<sup>2</sup>: 17.0%) in the TUS using an AFO compared to no AFO (Figure 4(a)). Subgroup analyses based on stroke phase (Supplemental Figure 5(a)), adaptation time (Supplemental Figure 5(a)), study quality (Supplemental Figure 5(a)), and walking speed (Supplemental Figure 5(a)) were also presented. For orthosis type, subgroup analysis was not applicable because the subgroups contained only a single study that used either an articulated orthosis or both articulated and non-articulated orthoses (mixed group).

**Motricity Index:** We excluded one study for meta-analysis because values for Motricity Index had not been reported, and we did not receive any responses from authors by email [51]. Eight trials included in two studies were involved in a meta-analysis for the effect of AFOs on Motricity index. Pooled results of an all trials combination identified a Motricity Index of 0.651 (95% CI 0.381– 0.922) with a significant improvement (SMD: 0.65, CI:0.38 to 0.92) and very low heterogeneity ( $I^2$ : 0.0%) after using an orthosis in comparison with before using the orthosis (Figure 4(b)). Subgroup analyses based on adaptation time (Supplemental Figure 6(a)) and study quality (Supplemental Figure 5(b)) were also presented.

#### 3.2.2. Results of qualitative analyses

For the following outcomes, a meta-analysis was not applicable because of the limitation in the number of studies for each parameter. Thus, we conducted a narrative analysis for these indices.

**Timed Down-Stairs (TDS):** Total time taken to go down 10 steps from the top of the stairs was recorded (in seconds). The effect of an AFO on this test between an orthotic intervention and a non-orthotic intervention was measured in only one study. Erel et al. reported no difference between wearing a dynamic supramalleolar AFO (13.29  $\pm$ 11.21) and a control group wearing only tennis shoes (15.36 $\pm$ 8.37) for the TDS test after a 3 month follow-up (p> 0.05) [46].

**Functional Reach Test (FRT):** This test measures the maximum distance a person can reach forward or to the side while standing in a fixed position. Only two papers evaluated the effect of using an AFO on this test. Rao et al. indicated that the mean maximal reaching distance in all the directions (forward, right, and left) was improved in subjects who have suffered a stroke, when provided with a non-articulated orthosis [30]. Another study reported that the outcome in the forward direction did not significantly change in the group wearing dynamic supramalleolar orthosis and tennis shoes  $(33.43\pm9.59 \text{ cm})$  compared with the control group wearing only tennis shoes  $(28.46\pm4.40 \text{ cm})$  [46].

Modified Ashworth scale: Only two studies reported spasticity after receiving an AFO along with training during the subacute stage. Sankaranarayan et al. reported that Modified

Ashworth scale (plantar flexors) did not significantly change (p=0.822) pre to post after an intervention including 14 training sessions (2 weeks) of activity based rehabilitation using rigid AFOs [26]. De Sèze et al. measured tricipital and quadricipital spasticity on the modified Ashworth scale at day 0, day 30, and day 90 in two orthotic groups. The results indicated a significant improvement in spasticity after a 3-month follow-up for the group with the Chignon AFO (p<0.05), but not for the group with the PLS-AFO [50].

**Functional Independence Measure (FIM):** Only two studies reported this function after receiving an AFO along with training during the subacute stage. One paper showed that the mean mobility scores of the FIM were significantly high at discharge than at admission for those who used an orthosis ( $26.0\pm4.7$  vs.  $18.9\pm6.6$ , p<0.001) [26]. Another paper in a randomized-controlled trial reported that FIM scores significantly improved after receiving PLS-AFO and Chignon AFO at 30 days of follow-up (p<0.05) [50].

The modified Emory Functional Ambulation Profile (mEFAP): The mEFAP comprises five timed tasks with different terrains: floor, carpet, TUG, obstacles and stairs. Only one study evaluated the effect of using an AFO on mEFAP in chronic stroke patients. The subscores of time in floor (p<0.001) and carpet (p = 0.013) trials significantly decreased with an orthotic intervention; no significant difference was observed in stair (p =0.067) and obstacle (p = 0.092) trials [29].

**Barthel Index, and Rivermead Mobility Index:** These indexes were measured using an AFO in two papers examining subacute stroke patients [47,48] and one paper examining patients in the chronic phase [45]. In a randomized-controlled trial, Nikamp evaluated an early versus delayed provision of a non-articulated orthosis (PLS-AFO or rigid AFO). A positive effect of

using the AFO was found on these indices for both early and delayed groups after two weeks of orthotic use [48]. In another study by Nikamp, the six-month clinical effects of providing AFOs in early versus delayed groups were evaluated. Patients with early provision of orthotics demonstrated a general trend towards earlier independence (about 12 weeks), but this difference was not statistically significant [47]. Everaert et al. reported that the Rivermead Mobility Index significantly increased over the 12 weeks of orthotic use (P < 0.001) [45].

#### 3.3. Comparing among different types or designs of AFO or shoes:

Orthotic types or designs used in each study were different from each other. Therefore, a meta-analysis based on the comparison between different types (non-articulated or articulated) of AFO was not possible. Seven studies compared effects of different orthoses or shoes on functional mobility. In Farmani's study, the TUG significantly improved when patients walked with a rigid AFO in a rocker shoe compared to a rigid AFO with a standard shoe [49]. Eckhardt et al. also reported that temporary high orthopaedic shoes with a stiff upper portion, made of carbon fiber, improved TUG score compared to normal shoes (22%; p <0.001) [44]. De Sèze et al. evaluated FAC at initial wearing time (day 0) and at 30 and 90 days of follow-up. The researchers stated that in the condition without an orthotic, the FAC score tended to be higher in the PLS-AFO group compared to Chignon AFO group, at 90-day follow-up. The difference did not reach significance in the condition with an orthosis. No significant differences were found between the two orthotic groups concerning the FIM, Motor index, and spasticity scores [50]. Slipper at al. reported that wearing an AFO that stopped plantarflexion resulted in significantly faster stair climbing (p=0.005) and longer walking distance in the 6MWT (p=0.016) compared to walking with a carbon fiber AFO [24]. Also, a pilot study by Shin reported that FRT and TUG scores improved significantly when wearing an AFO with plantarflexion stop compared with a

rigid orthosis (p<0.01) [27]. In Karakkattil's study, no significant differences were found between the PLS-AFO and the AFO with plantarflexion stop for endurance and gait velocity at both baseline, and after a week of practice during the subacute phase of stroke recovery. However, there was a significant improvement between the baseline measurement and the 1week practice measurement for both parameters (p<0.001), regardless of the orthotic design [42]. In another study, there were no significant differences between prefabricated AFOs with plantarflexion stop and custom-made AFOs with plantarflexion stop for the TUG test (p>0.05) [40].

#### 3.4. Assessment of publication bias

The findings demonstrated no evidence of potential publication bias (p > 0.05) for the trials included in each outcome, except for FAC (p < 0.05) (Supplemental Table 7). Funnel plots for the BBS, TUG, and FAC are presented in Supplemental Figure 8. Egger's linear graphs for the 6MWT, TUS, and Motricity Index are illustrated in Supplemental Figure 9.

#### 4. Discussion

In this review, functional outcomes based on clinical measurements such as walking endurance, independence of walking, functional mobility, balance, motor index, mobility during ADLs, and muscle strength were selected. These measures are easy to perform, require little equipment, and appear to be clinically feasible and reliable for providing the evidence of improved functional performance following clinical treatment [11,53]. In addition, wide ranges of walking capacity can be evaluated using these tests, including endurance, velocity, and different walking environments (such as walking over uneven surfaces and stair-climbing), thereby providing a clearer picture of real-life mobility issues.

#### 4.1. Quantitative analyses

#### 4.1.1. Combined analyses

Current overall pooled results suggest that using an AFO provided a significant improvement in all functional outcomes compared with no orthosis. It could be expected that wearing an AFO would result in a greater contribution of the affected lower extremity to stabilize the body during mobility and quiet standing. Although the overall analysis demonstrates statistically significant differences, the clinical significance for some parameters remains uncertain because SMDs were small (a few degrees of movement in the forest plot). It is not clear whether such changes are sufficient at providing a meaningful difference in functional ambulation for individuals who have previously suffered a stroke. Nevertheless, our analysis, which contained many of the same trials, showed improvements in the 6MWT, FAC, BBS, and Motricity Index. These improvements suggested that changes could sufficiently be translated into function (SMD>0.5). Heterogeneity was not significant in the 6MWT, TUG, TUS, and Motricity Index ( $I^2 < 50\%$ , p>0.05). However, a significant heterogeneity was observed in the BBS and FAC. We attempted to describe the heterogeneity by subgrouping our findings based on included factors. Unfortunately, our ability to describe heterogeneity was restricted because of the nonhomogeneity in a number of the subgroup analyses (i.e., subgroups contained only a single trial or a single subgroup included all trials). Moreover, there was a big difference in the number of trials between each subcategory in some of the subgroup analyses. Therefore, the strength of our conclusion depends more on the overall pooled analysis.

#### 4.1.2. Subgroup analyses

Where subgroup analyses were relevant, subgrouping data based on adaptation time revealed that wearing an AFO has demonstrated better results on all outcomes in long-term adaptation, except for the TUG test, which is a substantial finding. In long-term adaptation, besides corrections of foot varus and foot-drop as well as improvements in mediolateral stability by computerized laboratory analyses reported in previous studies[8,9], functional ambulation improved as the patients' familiarization with the AFO increased. Regarding the quality in subgroup analyses, better results were revealed for trials with good quality, except for the TUG test. Moreover, subgrouping data based on patient walking velocity before the use of an AFO indicated that most trials which recruited patients in the subacute phase had walking speeds in the household ambulation category (<0.4 m/s). On the other hand, most papers evaluating the rehabilitation care of training while using an AFO recruited participants in the subacute recovery phase, but not in the chronic post stroke phase. This finding suggests that early mobility training with an AFO is effective possibly in view of the very active functional and neurological recovery occurring during this time. Subgrouping data revealed that individuals in the subacute stroke phase, as well as those with walking speeds within the household ambulatory category, would demonstrate better results compared to the limited-community speeds (0.4-0.8 m/s) for most of the outcomes, except for the TUG test. Thus, rehabilitative care involving gait training while wearing an AFO could have beneficial effects on the functional outcomes of individuals who have had a stroke and are in an early course of recovery. However, the evaluation of the outcomes for orthotic rehabilitative care in the subacute phase was based on the results of four studies [36,47,48,50] with fair to good quality. Two studied did not state whether subjects were receiving rehabilitation [33,43]. Hence, this finding should be interpreted cautiously. For the TUG subgroup, the findings were different from other parameters in some instances, with better results in chronic stroke patients and the immediate effect of AFO. This finding suggests that the TUG test is a more complex skill than other functional outcomes requiring more strength and balance, which may be recovered later in the rehabilitation timeline for post-stroke individuals. Although this is a logical conclusion, the rigorous support for this speculation is weak because of a fairly large difference in the number of trials between each subcategory in some of the subgroup analyses (Supplemental table 2). Additional research effort is clearly needed to determine when individuals with post-stroke impairments reacquire walking skills as opposed to more difficult mobility skills, such as rising from a chair, which may require additional strength and balance recovery.

Although various AFO designs could improve functional mobility in some way, subgroup analysis of orthotic types (non-articulated versus articulated) was not possible for four outcomes including the BBS, 6MWT, TUS, and Motricity Index. When subgroup analysis of orthotic type was applied for the TUG and FAC, an articulated AFO demonstrated better results on the TUG test. There was no significant difference found on FAC. This result may be due to the increased dorsiflexion an articulated orthosis can allow, but how an articulated orthosis can improve the TUG test and FAC is not completely understood. It is believed that orthotic types or designs should be determined based on specific clinical problems and adjusted for each individual based on pathomechanics and gait mechanics in the clinical setting. However, there is not sufficient evidence that a certain orthotic type or design is more effective than others in post-stroke individuals. Additionally, several different AFO designs were grouped together in the nonarticulated category, ranging from rigid AFOs to dynamic supramalleolar AFOs. Although biomechanical features and restrictions embedded in these AFO designs are very different, it was not possible to make a subgroup within the non-articulated category due to the big difference in number of trials between potential subcategories. Future studies should investigate how specific types or designs of AFOs can benefit specific categories of deficits to develop an effective clinical treatment paradigm in post-stroke individuals.

In this meta-analysis, we focused on the stroke recovery phase, the orthotic type, the adaptation time with AFOs, quality of studies based on Downs and Black checklist, and walking speeds before using an AFO as sources which may explain heterogeneity. However, other potential factors of heterogeneity could have also been evaluated such as hemiparesis and spasticity, cognitive ability, stroke type, differences in walking ability, gender, history of orthotic use, history of gait training, or the degree of familiarization with AFOs (habituation vs. first-time use). Nevertheless, these factors were not consistently stated in all of the included studies.

The strength in the conclusion of reviewed studies depends on the data completeness. We contacted authors for further data because values for some parameters had not been reported in some papers. Unfortunately, we did not receive a response from some of the authors. Based on the results, however, there was not a potential publication bias in any of the outcomes, except for the FAC.

#### 4.2. Qualitative analyses

## 4.2.1. Comparison of AFO versus without AFO

Although evidence was largely insufficient for reaching a valid conclusion, the scores of the FIM [26,50], mEFAP [29], spasticity [26,50], Barthel Index [47,48], and Rivermead Mobility Index [45,47,48] were statistically improved using an AFO for the short duration category (up to 3-month follow up). All of the studies, except one [29], included patients concurrently receiving physical rehabilitation training supervised by a physiotherapist. Therefore, the improvements of

functional performance likely reflect the recovery process after a stroke and the effectiveness of rehabilitation care using an AFO. However, divergence in the results of two studies for FRT was revealed with the use of an AFO in chronic stroke patients. One study reported a significant increase in the maximal reaching distance in all directions (forward, right, and left) with an AFO [30]. However, a randomized-controlled trial did not find a significant difference in the forward direction [46]. Reaching activities are associated with a shift in ones center of gravity while remaining inside the respective base of support. The central nervous system utilizes movement strategies by either using a step strategy to make a new base of support or realigning the center of gravity within the current base of support to maintain functional stability. An appropriate movement strategy cannot be achieved in individuals with a history of a stroke who have stability impairments [54]. Although AFOs seem to exert positive effects on the alignment of an ankle-foot complex, it is not clear whether using an AFO can improve reaching activities. Additionally, the relationship between reaching distance and center of gravity on limits of stability using an orthotic intervention requires additional evaluation in future studies before definitive conclusions can be reached.

Finally, although spasticity could be reduced by rehabilitation care and also naturally in the course of recovery, only a few studies with fair to poor quality have addressed this [26,50]. We assume that an AFO might have an indirect effect on spasticity by assisting patients to be more active and allow them to perform more rehabilitation and exercise. However, strong evidence is needed to support this hypothesis. Influence of an AFO on spasticity of the lower-limb joints would be an interesting topic for future studies [55].

# 4.2.2. Comparing among different types or designs of AFO or shoes

Concerning the comparisons among orthotic types conducted by the narrative analysis, the findings of the evaluated studies suggested that the articulated AFOs resulted in greater improvement in some functional outcomes including the TUG test [27], stair climbing [24], and walking endurance [24] compared to walking with non-articulated orthoses. However, the scientific rigor of this evidence is weak. One study reported no significant differences between the PLS-AFO and AFO with plantarflexion stop for endurance at baseline and after 1-week of practice during the subacute phase of recovery [42]. A previous review reported beneficial orthotic effects of articulated orthoses on gait parameters by providing dorsiflexion assistive force and preventing excessive plantarflexion compared with non-articulated orthoses [8]. On the other hand, despite the Chignon AFO group having a higher walking velocity, one study reported that the FAC score was higher in the PLS-AFO group compared to the Chignon AFO group when not wearing an AFO at day 90 [50]. Such changes over time measured when not wearing an orthosis are referred to as a therapeutic effect. Further studies on the therapeutic effect of an AFO based on training should be encouraged, especially in understanding the characteristics of the patient that might help guide the selection and tuning of an AFO for their specific pathomechanics. Regarding the different shoes used with an AFO, two studies reported improvement of the TUG test with the use of a rocker shoe[49] or an orthopaedic shoe[44] compared with a standard shoe. Nevertheless, the orthosis used in Farmani et al. was rigid and limits some motion for functional benefits. Despite the improvement of functional mobility in these studies, it is not clear whether wearing rocker shoes may disturb patient balance after a stroke.

#### 5. Limitations

The main limitations of the current review were related to the nature of data, as previously mentioned. There was a big difference in the number of trials between each subcategory in many of the subgroup analyses. This issue restricted our conclusions based on the subgroup analysis. Most trials assessed effects of AFOs without gait training and had a small sample size. Risk of bias was high and scientific rigor, weak to fair. They were with high risk of bias and weak to fair in scientific rigor. Blinding is difficult for the patients because of the nature of the intervention. However, investigators should be blinded to the types and designs of orthoses, if possible. Those conducting clinical measurements of functional mobility and processing the data should not know the orthotic condition of the participants. These formal structures to blind investigators were absent for all research designs evaluated in this systematic review. Using an AFO along with gait training in the subacute phase may improve the patients' walking ability, although the long-term effects of an AFO in this phase were reported in only a few studies. Only five papers calculated a power analysis to specify the appropriate sample size for the intervention [36,42,45,46,49]. No trial investigated the efficacy of an AFO with variable plantarflexion resistances on the included variables. Only one trial evaluated the effect of using an AFO on different terrains [29]. Further, the AFO-footwear combination would have different clinical effects on functional ambulation depending on gait patterns [49]. Nevertheless, some studies only investigated gait with an AFO, while others examined walking with footwear in addition to an orthosis. Finally, the comparison among various types or designs of AFOs as well as the comparison between the non-articulated and articulated orthoses on functional mobility after a stroke was investigated in few studies.

# 6. Recommendations for future research

Based on the findings of this systematic review and meta-analysis, future research should:

- Focus on randomized-controlled trials with low risk of bias, blinding the assessors' during measurements, random assignments, and preventing loss in follow-up;
- Investigate effects of long-term training (6-12 months or more) of wearing AFOs in chronic and (sub) acute stages;
- Compare early or delayed provision of AFOs on the walking ability of individuals with a stroke;
- Compare physical function of patients in chronic phase who continue to use AFOs and who quit using them;
- Evaluate walking over different terrains using an AFO;
- Relationship between reaching distance and center of gravity using an AFO during daily activities;
- Evaluate a comparison among different types or designs of orthotics on functional outcomes;
- Evaluate the effects of AFOs when not wearing them after training (carry-over effects); and
- Investigate the effect of rocker shoes with AFOs on walking balance after a stroke.

# 7. Conclusion

This systematic review and meta-analysis supports that an AFO can improve functional performance and ambulation in survivors of strokes and that an AFO is more effective on functional outcomes with long-term adaptation. Wearing an AFO in rehabilitation care during the subacute phase may have beneficial effects on clinical outcomes measured in individuals with a history of a stroke. There was insufficient evidence to conclude which effects different types or designs of orthotics had on functional outcomes. A number of areas in research methodologies need to be addressed in future studies in order to provide further evidence as to the effects of AFOs on functional outcome measures.

## References

- [1] de Oliveira CB, de Medeiros ÍRT, Ferreira NA, Greters ME, Conforto AB. Balance control in hemiparetic stroke patients: main tools for evaluation. Journal of Rehabilitation Research & Development 2008;45.
- [2] Weerdesteijn V, Niet Md, Van Duijnhoven H, Geurts AC. Falls in individuals with stroke. 2008.
- [3] Bohannon RW, Morton MG, Wikholm JB. Importance of four variables of walking to patients with stroke. International Journal of Rehabilitation Research 1991;14:246-50.
- [4] Mumma CM. Perceived losses following stroke. Rehabilitation Nursing 1986;11:19-24.
- [5] Mauritz K. Gait training in hemiparetic stroke patients. European Journal of Physical and Rehabilitation Medicine 2004;40:165.
- [6] van Bloemendaal M, van de Water AT, van de Port IG. Walking tests for stroke survivors: a systematic review of their measurement properties. Disability and rehabilitation 2012;34:2207-21.
- [7] Ferrarello F, Bianchi VAM, Baccini M, Rubbieri G, Mossello E, Cavallini MC, Marchionni N, Di Bari M. Tools for observational gait analysis in patients with stroke: a systematic review. Physical therapy 2013;93:1673-85.
- [8] Daryabor A, Arazpour M, Aminian G. Effect of different designs of ankle-foot orthoses on gait in patients with stroke: A systematic review. Gait & posture 2018;62:268-79.
- [9] Tyson S, Sadeghi-Demneh E, Nester C. A systematic review and meta-analysis of the effect of an ankle-foot orthosis on gait biomechanics after stroke. Clinical rehabilitation 2013;27:879-91.
- [10] Daryabor A, Yamamoto S, Orendurff M, Kobayashi T. Effect of types of ankle-foot orthoses on energy expenditure metrics during walking in individuals with stroke: a systematic review. Disability and Rehabilitation 2020:1-11.
- [11] Eng JJ, Chu KS, Dawson AS, Kim CM, Hepburn KE. Functional walk tests in individuals with stroke: relation to perceived exertion and myocardial exertion. Stroke 2002;33:756-61.
- [12] Lin JH, Hsu MJ, Hsu HW, Wu HC, Hsieh CL. Psychometric comparisons of 3 functional ambulation measures for patients with stroke. Stroke 2010;41:2021-5.
- [13] Tyson SF, Kent RM. Effects of an ankle-foot orthosis on balance and walking after stroke: a systematic review and pooled meta-analysis. Archives of physical medicine and rehabilitation 2013;94:1377-85.

- [14] Ferreira LAB, Neto HP, Christovão TCL, Duarte NA, Lazzari RD, Galli M, Oliveira CS. Effect of ankle-foot orthosis on gait velocity and cadence of stroke patients: a systematic review. Journal of physical therapy science 2013;25:1503-8.
- [15] Alam M, Choudhury IA, Mamat AB. Mechanism and design analysis of articulated ankle foot orthoses for drop-foot. The Scientific World Journal 2014;2014.
- [16] Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology & Community Health 1998;52:377-84.
- [17] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology 2014;14:135.
- [18] Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of clinical epidemiology 2001;54:1046-55.
- [19] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994:1088-101.
- [20] Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997;315:629-34.
- [21] Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the stroke population. Stroke 1995;26:982-9.
- [22] Shahabi S, Shabaninejad H, Kamali M, Jalali M, Ahmadi Teymourlouy A. The effects of ankle-foot orthoses on walking speed in patients with stroke: a systematic review and meta-analysis of randomized controlled trials. Clinical Rehabilitation 2020;34:145-59.
- [23] Maeda N, Kato J, Azuma Y, Okuyama S, Yonei S, Murakami M, Shimada T. Energy expenditure and walking ability in stroke patients: Their improvement by ankle-foot orthoses. Isokinetics and Exercise Science 2009;17:57-62.
- [24] Slijper A, Danielsson A, Willén C. Ambulatory function and perception of confidence in persons with stroke with a custom-made hinged versus a standard ankle foot orthosis. Rehabilitation research and practice 2012;2012.
- [25] Doğğan A, MengüllüoĞĞlu M, Özgirgin N. Evaluation of the effect of ankle-foot orthosis use on balance and mobility in hemiparetic stroke patients. Disability and rehabilitation 2011;33:1433-9.
- [26] Sankaranarayan H, Gupta A, Khanna M, Taly AB, Thennarasu K. Role of ankle foot orthosis in improving locomotion and functional recovery in patients with stroke: A prospective rehabilitation study. Journal of neurosciences in rural practice 2016;7:544.
- [27] Shin YJ, Lee DH, Kim M-K. The effect of newly designed multi joint ankle foot orthosis on the gait and dynamic balance of stroke patients with foot drop. Journal of physical therapy science 2017;29:1899-902.
- [28] Cakar E, Durmus O, Tekin L, Dincer U, Kiralp M. The ankle-foot orthosis improves balance and reduces fall risk of chronic spastic hemiparetic patients. Eur J Phys Rehabil Med 2010;46:363-8.
- [29] Sheffler LR, Hennessey MT, Naples GG, Chae J. Peroneal nerve stimulation versus an ankle foot orthosis for correction of footdrop in stroke: impact on functional ambulation. Neurorehabilitation and neural repair 2006;20:355-60.
- [30] Rao N, Aruin A. Role of ankle foot orthoses in functional stability of individuals with stroke. Disability and Rehabilitation: Assistive Technology 2016;11:595-8.
- [31] Tomioka K, Matsumoto S, Ikeda K, Uema T, Sameshima J-i, Sakashita Y, Kaji T, Shimodozono M. Short-term effects of physiotherapy combining repetitive facilitation exercises and orthotic treatment in chronic post-stroke patients. Journal of physical therapy science 2017;29:212-5.
- [32] Hale J, Seale J, Jennings J, DiBello T. An advanced ground reaction design ankle-foot orthosis to improve gait and balance in individuals with post-stroke hemiparesis: a case series. JPO: Journal of Prosthetics and Orthotics 2013;25:42-7.
- [33] Hyun CW, Kim BR, Han EY, Kim SM. Use of an ankle-foot orthosis improves aerobic capacity in subacute hemiparetic stroke patients. PM&R 2015;7:264-9.

- [34] Simons CD, van Asseldonk EH, van der Kooij H, Geurts AC, Buurke JH. Ankle-foot orthoses in stroke: effects on functional balance, weight-bearing asymmetry and the contribution of each lower limb to balance control. Clinical Biomechanics 2009;24:769-75.
- [35] Tyson S, Thornton H. The effect of a hinged ankle foot orthosis on hemiplegic gait: objective measures and users' opinions. Clinical Rehabilitation 2001;15:53-8.
- [36] Tyson SF, Rogerson L. Assistive walking devices in nonambulant patients undergoing rehabilitation after stroke: the effects on functional mobility, walking impairments, and patients' opinion. Archives of physical medicine and rehabilitation 2009;90:475-9.
- [37] Abe H, Michimata A, Sugawara K, Sugaya N, Izumi S-I. Improving gait stability in stroke hemiplegic patients with a plastic ankle-foot orthosis. The Tohoku journal of experimental medicine 2009;218:193-9.
- [38] Assawapalangchai S, Phulsawat W, Charatrungolanb T, Srithamboonb S. The effects of anterior ankle foot orthosis on gait parameters, walking ability, and patient satisfaction of Thai stroke patients, Siriraj hospital. Siriraj Medical Journal 2017;64:123-6.
- [39] Pavlik AJ. The effect of long-term ankle-foot orthosis use on gait in the poststroke population. JPO: Journal of Prosthetics and Orthotics 2008;20:49-52.
- [40] Pardo V, Galen S, Gahimer JE, Goldberg A. Effects of custom-molded and prefabricated hinged ankle-foot orthoses on gait parameters and functional mobility in adults with hemiplegia: a preliminary report. JPO: Journal of Prosthetics and Orthotics 2015;27:33-8.
- [41] Yue L, XU G-q, Huang D-f, Mao Y-r, Chen S-z, Zhong P, Zeng J-s. Association between improved trunk stability and walking capacity using ankle-foot orthosis in hemiparetic patients with stroke: evidence from three-dimensional gait analysis. Chinese medical journal 2013;126:3869-73.
- [42] Karakkattil PS, Trudelle-Jackson E, Medley A, Swank C. Effects of two different types of ankle–foot orthoses on gait outcomes in patients with subacute stroke: a randomized crossover trial. Clinical Rehabilitation 2020;34:1094-102.
- [43] Wang R-Y, Yen L-L, Lee C-C, Lin P-Y, Wang M-F, Yang Y-R. Effects of an ankle-foot orthosis on balance performance in patients with hemiparesis of different durations. Clinical rehabilitation 2005;19:37-44.
- [44] Eckhardt MM, Mulder MCB, Horemans HL, van der Woude LH, Ribbers GM. The effects of high custom made shoes on gait characteristics and patient satisfaction in hemiplegic gait. Gait & posture 2011;34:543-7.
- [45] Everaert DG, Stein RB, Abrams GM, Dromerick AW, Francisco GE, Hafner BJ, Huskey TN, Munin MC, Nolan KJ, Kufta CV. Effect of a foot-drop stimulator and ankle–foot orthosis on walking performance after stroke: a multicenter randomized controlled trial. Neurorehabilitation and neural repair 2013;27:579-91.
- [46] Erel S, Uygur F, Engin Şimşek İ, Yakut Y. The effects of dynamic ankle-foot orthoses in chronic stroke patients at three-month follow-up: a randomized controlled trial. Clinical rehabilitation 2011;25:515-23.
- [47] Nikamp CD, Buurke JH, van der Palen J, Hermens HJ, Rietman JS. Six-month effects of early or delayed provision of an ankle-foot orthosis in patients with (sub) acute stroke: a randomized controlled trial. Clinical rehabilitation 2017;31:1616-24.
- [48] Nikamp CD, Buurke JH, van der Palen J, Hermens HJ, Rietman JS. Early or delayed provision of an ankle-foot orthosis in patients with acute and subacute stroke: a randomized controlled trial. Clinical rehabilitation 2017;31:798-808.
- [49] Farmani F, Mohseni Bandpei MA, Bahramizadeh M, Aminian G, Nikoo MR, Sadeghi-goghari M. The effect of different shoes on functional mobility and energy expenditure in post-stroke hemiplegic patients using ankle–foot orthosis. Prosthetics and orthotics international 2016;40:591-7.
- [50] De Sèze M-P, Bonhomme C, Daviet J-C, Burguete E, Machat H, Rousseaux M, Mazaux JM. Effect of early compensation of distal motor deficiency by the Chignon ankle-foot orthosis on gait in hemiplegic patients: a randomized pilot study. Clinical Rehabilitation 2011;25:989-98.

- [51] de Wit DC, Buurke J, Nijlant JM, IJzerman MJ, Hermens HJ. The effect of an ankle-foot orthosis on walking ability in chronic stroke patients: a randomized controlled trial. Clinical rehabilitation 2004;18:550-7.
- [52] Nevisipour M. Evaluating the Effects of Ankle-Foot-Orthoses, Functional Electrical Stimulators, and Trip-Specific Training on Fall Outcomes in Individuals with Stroke: Arizona State University; 2019.
- [53] Lamola G, Bertolucci F, Rossi B, Chisari C. Clinical assessments for predicting functional recovery after stroke. Int J Neurorehabil 2015;2:174.
- [54] Corriveau H, Hébert R, Raiche M, Prince F. Evaluation of postural stability in the elderly with stroke. Archives of physical medicine and rehabilitation 2004;85:1095-101.
- [55] Kobayashi T, Leung AK, Hutchins SW. Design and effect of ankle-foot orthoses proposed to influence muscle tone: a review. JPO: Journal of Prosthetics and Orthotics 2011;23:52-7.
- [56] Lan Y, Xu GQ, Huang DF, Mao YR, Chen SZ, Pei Z, Zeng JS. Association between improved trunk stability and walking capacity using ankle-foot orthosis in hemiparetic patients with stroke: evidence from three-dimensional gait analysis. Chin Med J (Engl) 2013;126:3869-73.

	Report					Extern Internal Validity- Bias al Validit y				Internal Validity – Confounding			Power	Total				
Quality Items	Q1	Q2	Q3	Q4	Q6	Q7	Q9	Q1 0	Q11	Q14	Q15	Q18	Q20	Q22	Q23	Q26	Q27	17 possible
	Hy pot hesi s/Ai m	Ma in Out co mes in Me th/ Int ro	Incl usi on /Ex clus ion Cri teri a	Des cri ptio n of Int erv enti ons	Mai n Find ings	Ran dom Vari abili ty	Los t to Foll ow- up	Act ual Pro bab ility Val ues	Represe ntative of the Entire Populati on	Blin d Stu dy Sub ject s	Blind those meas uring	Statis tical Tests Appr opria ted	Outc ome Meas ures Used Accu rate	Sam e Peri od of time	Ran dom Allo cati on	Losse s of Patie nts to Follo w-up	Estimate of Statistica 1 Power	-
Farmani (2016)[4 9]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	1	1	1	13
Hyun(2 015)[33]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	0	1	0	10
Maeda( 2015)[2 3]	1	1	1	1	1	0	1	0	0	0	0	1	1	0	0	1	0	9
Erel(201 1)[46]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	1	1	1	12
Slijper(2 012)[24]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Simons( 2009)[3 4]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	0	1	0	10
Tyson(2 009)[36]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	1	12
Doğan(2 011)[25]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Abe(200 9)[37]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	0	1	0	10

# Table 1. Modified Downs and Black Quality Index Results and Total Score

Tyson(2 001)[35]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Assawa palangc hai(201 7)[38]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
de Sèze(20 11)[50]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	1	1	0	11
Pavlik(2 008) [39]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
de Wit(200 4)[51]	1	1	1	1	1	1	1	1	0	0	0	0	1	1	1	1	0	12
Pardo(2 015)[40]	1	1	1	1	1	1	1	0	0	0	0	0	1	0	0	1	0	9
Sankara narayan( 2016)[2 6]	1	1	1	1	0	0	1	1	0	0	0	1	1	1	0	1	0	10
Yue(201 3)[56]	1	1	1	1	1	1	1	0	0	0	0	1	1	0	0	1	0	10
Nkamp( 2017)[4 7]	1	1	1	1	1	1	1	1	0	0	0	1	1	1	1	1	0	13
Nikamp (2017)[4 8]	1	1	1	1	1	1	1	1	0	0	0	1	1	1	1	1	0	13
Shin(20 17)[27]	1	1	1	1	0	1	1	0	0	0	0	1	1	0	0	1	0	9
Karakka ttil(2018 )[42]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	1	12
Hale(20 13)[32]	1	1	1	1	1	0	1	0	0	0	0	0	1	0	0	1	0	8
Cakar(2 010)[28]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Wang(2 005)[43]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11

Sheffler (2006)[2 9]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Rao (2016)[3 0]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11
Eckhard t(2011)[ 44]	1	1	1	1	1	0	1	1	0	0	0	1	1	0	0	1	0	10
Tomiok a(0217)[ 31]	1	1	1	1	1	0	1	0	0	0	0	1	1	0	0	1	0	9
Everaert (2013)[4 5]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	1	1	1	13
Nevisip our(201 9)[52]	1	1	1	1	1	1	1	1	0	0	0	1	1	0	0	1	0	11

1=YES, 0= NO, 0= Unable to determine

Author / Year	Study design	Samples	Stroke phase	Adaptation time for AFO use or shoe	AFO Design	Measures	Walking speed (m/s) in mean (SD): no AFO and with AFO	Qualit y status
(2016)[4 9]	Randomized, parallel-group controlled design (RCT)	30 individuals (M: 19, F: 11) with chronic stroke, were able to walk independently without assistive devices, mean age:59.3 years, mean time from stroke: 29.1 months, MAS:3 Group I (n:15): SS +RAFO Group II (n:15): RS+RAFO	Chronic	Not adopted (Immediate)	RAFO	-TUG (s) -Stairs (TUS and TDS) (s)	-Group I: AFO+SS: 0.64 (0.14) -Group II: AFO+RS: 0.71 (0.32)	good
15)[33]	Randomized clinical trial (quasi- experimental)	<ul> <li>15 individuals (M:12, F:3) with subacute stroke, the ability to walk at least 3 minutes with or without an aid, but without standby assistance, mean age: 62.1 years, time from stroke: 34.4days, ankle dorsiflexor muscle weakness grade of "less than fair", MAS: nr</li> <li>-Not stated whether subjects were undergoing rehabilitation</li> </ul>	Subacute	Immediate	RAFO	6MWT (m)	-No AFO: 0.73 (0.23) -With AFO: 0.82 (0.29)	poor
009)[23]	Non- Randomized clinical trial (quasi- experimental	18 individuals (M: 15, F: 3) with chronic stroke, able to walk without assistance, mean age: 45yeras, time from stroke: 19 months, MAS: nr BS: 3-5	Chronic	Habituated to walking with a PAFO for 8 months	PAFO	6MWT (m)	- No AFO: 0.38 (0.2) -AFO: 0.48 (0.2)	poor
(2011)[4 6]	Randomized, parallel-group controlled design (RCT)	<ul> <li>28 individuals (M: 18, F: 10) with chronic stroke were classified into 2 groups:</li> <li>CG: mean age:50.64 years, time from stroke: 25.36 months</li> <li>SG: mean age: 42.50 years, time from stroke: 30.21 months, MAS:3, FAC: 3-5</li> <li>CG (M: 7, F:7): only tennis shoe (n:14)</li> <li>SG (M: 11, F:3): tennis shoe +AFO (n:14)</li> </ul>	Chronic	Three months	DAFO (Supramalleolar orthosis) based on tone-inhibiting orthosis		-Initial assessment: CG: 0.65 (0.19) SG: 0.84 (0.40) -After 3 months: CG: 0.72 (0.20) SG: 0.99 (0.45)	fair
012)[24]	Non- clinical trial (quasi- experimental	12 individuals (M:2, F:10) with chronic stroke, able to walk for at least 6 minutes without personal assistance (walking aid was allowed), mean age:56years, mean time from stroke: 25months, MAS: 0-3	Chronic	-Time with AFO-PS:2.5 months -Time with C-AFO:3 months	- CAFO - AFO-PS	-6MWT(m) -Stairs (s) (TUS)	-CAFO: 0.55 (0.28) -AFO-PS: 0.59 (0.25)	fair

# Table 2: Characteristics of the Studies on the Effect of AFOs on Functional Outcome Measurements

(2009)[3 4]	Randomized clinical trial (quasi- experimental		Chronic	Worn an AFO in everyday life, mean > for 3 months	-PLS-AFO -RAFO -Metal AFO-PS	-TUG(s) -FAC (score) -BBS (score)	- No AFO: 0.46 (0.21) -AFO: 0.58 (0.24)	poor
009)[36]	Randomized clinical trial (quasi- experimental	20 individuals (M: nr, F: nr) with subacute stroke undergoing rehabilitation care, able to walk 5m without physical support, mean age: 65.6yeras, mean time from stroke: 6.5weeks, Motricity index: 48.1, MAS: nr	Subacute	The morning before testing (Immediate effect)	-Cane -PLS-AFO -Slider shoe -A combination of all 3 devices	FAC(score)	-No device: 0.3 (0.14) -Cane: 0.28 (0.15) -AFO: 0.30 (0.12) -Slider shoe: 0.31 (0.13) -All devices: 0.29 (0.14)	fair
(2011)[2	Non- clinical trial (quasi- experimental	51 individuals (M:24, F:27) with subacute stroke, able to ambulate, mean age: 60.7years, mean time from stroke: 69days, MAS: 1-3	Subacute	4 days	AFO-PS	-TUG(s) -Ashburn climbing stairs (7 stairs) (s) -BBS (score)	- No AFO: 0.29 -AFO:0.32	fair
9)[37]	Randomized clinical trial (quasi- experimental	16 individuals (M:11, F:5) with chronic stroke, ability to walk at least 8m, mean age: 55.9years, mean time from stroke: 49.5months, BS:3-4, passive ROM for ankle dorsiflexion: 0-20, FAC: 3-4, MAS: nr	Chronic	At least 2 weeks	-PLS-AFO (n:9) -AFO-PS (n:7)	FAC(score)	- No AFO:0.30 (0.13) -AFO:0.38 (0.11)	poor
001)[35]	Randomized clinical trial (quasi- experimental	25 individuals (M:16, F:9) with subacute/chronic stroke, ability to weight bear and step with weak leg (but may be unable to have a functional gait pattern), mean age: 49.9 years, mean time from stroke: 8.3months, MAS: nr	Subacute/chro nic	Participants wore an AFO in everyday life for at least 1 month before testing	AFO-PS	FAC(score)	- No AFO: 0.18 (0.1) -AFO: 0.25 (0.1)	fair
Assawap alangcha	Randomized clinical trial (quasi- experimental	21 individuals (M:13, F:8) with subacute/chronic stroke, able to walk at least 10 meters with intermittent support, but without standby assistance, mean age: 59.8 years, time from stroke: 3-39months, MAS: nr	Subacute/chro nic	2-week for familiarization	Flexible AAFO	FAC(score)	- No AFO: 0.13 (0.063) -AFO: 0.13 (0.061)	fair

Sèze(201 1)[50]	Randomized, parallel-group controlled design (RCT)	<ul> <li>28 individuals (M: 18, F: 10) with subacute stroke and plantar flexion spasticity undergoing rehabilitation care, able to walk&gt;10 m</li> <li>SG (Chignon AFO): 13 subjects (M:11, F:2), mean age:56.4 years, mean time from stroke:104.4 days</li> <li>CG (PLS-AFO): 15 subjects (M:7, F:8), mean age: 53 years, mean time from stroke: 56 days</li> <li>MAS ≥3</li> </ul>	Subacute	30 and 90 days of follow-up	-Chignon AFO: SG -PLS-AFO: CG	-FAC(score) - Motricity index (score) -Spasticity (score) -FIM (score)	<ul> <li>No AFO in day</li> <li>Chignon AFO group: 0.10*;</li> <li>AFO-PLS group: 0.12*</li> <li>With AFO in day 30: Chignon AFO group: 0.25*; AFO-PLS group: 0.16*</li> <li>With AFO in day 90: Chignon AFO group: 0.30*; AFO-PLS group: 0.30*; aFO-PLS group: 0.22*</li> </ul>	fair
(2008)[3 9]	Randomized clinical trial (quasi- experimental	4 individuals (M: 3, F: 1) with chronic stroke, ability to independently ambulate with and without their AFO (the use of other assistive devices was permitted for safety), mean age: 60years, mean time from stroke: 75months, MAS: nr	Chronic	Participants wore an AFO for at least 6 months before study	-RAFO: Right hemiplegia -AFO-PS: left hemiplegia	TUG (s)	- No AFO: 0.33(0.27) -AFO: 0.55(0.39)	poor
(2004)[5 1] Pardo (2015)[4 0]	Randomized, parallel-group controlled design (RCT) Randomized clinical trial (quasi- experimental	20 individuals (M:12, F:8) with chronic stroke, ability to walk independently recruited from rehabilitation centers, mean age: 61years, mean time from stroke: 26 months, MAS: nr Group I: walking with AFO (n:10) Group II: walking without AFO (n:10) 14 chronic stroke subjects (M:9, F:5), able to bear weight and step with the paretic leg, mean age: 55.7years, mean time from stroke: 13.5months, ability to achieve a		All wore an AFO in everyday life for at least 6 months Current use of a custom-made	PAFO (PLS-AFO or RAFO) -Custom-made AFO-PS -Prefabricated	-TUG (s) -Stairs (TUS and TDS) (s) -Motricity index(score) - FAC(score) TUG(s)	-No AFO:0.44(0.24) -AFO:0.49(0) -No AFO:0.53( 0.07) -Custom-made	fair poor
		neutral ankle (at least 0 degrees of dorsiflexion), MAS: nr		AFO, time: nr -Prefabricated AFO-PS: immediate	AFO-PS		AFO-PS: 0.66 (0.08) -Prefabricated AFO-PS: 0.63 (0.07)	
arayan(2	Non- clinical trial (quasi- experimental	26 (M:21, F:5) individuals with chronic and sub-acute stroke undergoing rehabilitation care, able to complete the walk tests, mean age: 41.6years, mean time from stroke: 196.7 days (minimum 6 weeks but not more than 1y ), MAS:+1	Subacute/chro nic	At least 2 weeks to get familiar with an AFO in rehabilitation center	RAFO	-Mobility FIM(score) -6MWT(m) -Spasticity (score)	-No AFO on admission: 0.40 -AFO on discharge: 0.51 - No AFO on discharge: 0.45	poor
(2013)[5 6]	Randomized clinical trial (quasi- experimental	20 individuals (M:11, F:9) with sub-acute stroke, ability to walk at least 10 m without assistance, mean age:55.3years, mean time from stroke: 5–15 weeks, BS: 3–5, MAS: nr	Subacute	30-minute sessions, twice a day, for 5 days	Molded plastic PAFO	-FAC(score) -BBS (score)	-No AFO: 0.48(0.19) -AFO: 0.59(0.21)	poor

				1			1	
2017)[47 ]	Randomized, parallel-group controlled design (RCT)	<ul> <li>33 individuals (M:20, F:13) with (sub)acute stroke undergoing rehabilitation care, mean age:57.2years, mean time from stroke:31.4days.</li> <li>-Early group (at inclusion; week 1):16</li> <li>-Delayed group (eight weeks later; week 9): 17, MAS: nr</li> </ul>	Subacute	Six-month clinical effects of early or delayed provision of an AFO	-PLS-AFO -RAFO	-FAC (score) -TUG(s) -6MWT(m) -Stair (TUS) (s) -BBS (score) -Motricity Index (score) -Barthel Index (score) -Rivermead Mobility Index (score)	-Early: no AFO: 0.16 (0.22), with AFO: 0.70 (0.36) -Delayed: no AFO: 0.22 (0.31), with AFO: 0.66 (0.31)	
2017)[48 ]	Randomized, parallel-group controlled design (RCT)	33 individuals (M:20, F:13) with (sub)acute stroke undergoing rehabilitation care, mean age:57.2years, mean time from stroke:31.4days, Motricity index: 30.3 -Early group (at inclusion; week 1):16 -Delayed group (eight weeks later; week 9): 17, MAS: nr	Subacute	Two weeks clinical effects of early or delayed provision of an AFO	-PLS-AFO -RAFO	-FAC(score) -TUG(s) -6MWT(m) -Stair (TUS) (s) -BBS(score) - Motricity index (score) -Barthel Index (score) -Rivermead Mobility Index (score)	-Early: no AFO: 0.16 (0.22), with AFO: 0.40 (0.31) -Delayed: no AFO: 0.22 (0.31), with AFO: 0.48 (0.25)	
7)[27]	Non- clinical trial (quasi- experimental	15 individuals (M:9, F:6) with chronic stroke, mean age: 58.53years, mean time from stroke: 10.53months, BS: 3–5, MAS: nr	Chronic	Immediate	-Traditional PAFO -AFO-PS	-TUG (s) -FRT (cm)	-PAFO:0.40* -AFO-PS: 0.53*	poor
til(2018) [42]	Randomized clinical trial (quasi- experimental	20 individuals (M:11, F:9) with subacute stroke, able to walk 20 feet without or with assistive device, mean age: 57.5years, mean time from stroke: 60days, MAS: nr	Subacute	One-week practice	- PLS-AFO -AFO-PS (DA)		-Baseline: AFO- PLS: 0.58(0.26), AFO-PS: 0.58(0.26) -After 1 week: PLS:0.66 (0.27), AFO-PS:0.70 (0.29)	fair
3)[32]	Non- clinical trial (quasi- experimental	5 individuals (M: 2, F: 3) with chronic stroke, able to walk at least 10m with supervision or assistive device, mean age: 56years, mean time from stroke: 25.4 months MAS: nr	Chronic	Immediate	Ground reaction design AFO	-TUG (s) -6MWT(m)	- No AFO: 0.53* -AFO: 0.82*	poor

Cakar(20 10)[28]	Non- clinical trial (quasi- experimental	25 individuals (M:17, F:8) with chronic stroke, ability to ambulate without assistive device, mean age: 60.52years, mean time from stroke: 20.32months, MAS:1-2, BS:2-3	Chronic	One week	PLS-AFO	BBS (score)	nr	fair
Wang(20 05)[43]	Randomized clinical trial (quasi- experimental	<ul> <li>-42 subjects (M:23, F:19) with short duration stroke (<!--6 months), able to ambulate for 10m with or without assistive device, mean age: 60.52years, mean time from stroke: 101.0days, MAS:1-2, BS:2-3</li--> <li>-61 subjects (M:51, F:10) with long duration stroke (&gt; 12 months), mean age: 59.9y, mean time from stroke: 1043.6days, MAS:1-2, BS: 2-3</li> <li>-Not stated whether subjects were undergoing rehabilitation</li> </li></ul>	-Subacute -Chronic	Immediate	RAFO		-Short duration stroke; No AFO: 0.58 (0.29), With AFO: 0.69 (0.41)/ -Long duration stroke; No AFO: 0.61 (0.27), With AFO: 0.71(0.34)/	fair
Sheffler( 2006)[29 ]	Non- clinical trial (quasi- experimental	14 individuals (M:9, F:5) with chronic stroke, able to walk at least 30 feet with minimal assistance, mean age: 56.7years, mean time from stroke: 30.8months, MAS: <4/5	Chronic	Immediate	-Prefabricated AFO (n:2) -Hinged AFO (n:4) -Plastic AFO (n:8)	(floor, carpet,		fair
Rao (2016)[3 0]	Non- clinical trial (quasi- experimental	23 individuals (M:11, F:12) with chronic stroke, able to ambulate at least 10m with or without assistive devices, mean age: 60.90 years, mean time from stroke: 7.8months, MAS:>2	Chronic	One month	-PAFO including RAFO (n:12) and PLS-AFO (n:11)	FRT (cm)	nr	fair
Eckhardt (2011)[4 4]	Randomized clinical trial (quasi- experimental	19 individuals (M:12, F:7) with subacute stroke, ability to walk minimum 20m in normal shoes with or without assistive device or supervision, mean age: 55 years, mean time from stroke: 3.6months, MAS:1, Motricity index: 53 -subjects were undergoing rehabilitation	Subacute	10 days	-Normal shoes -Orthopaedic shoe	- TUG (s)	-Normal shoes: 0.28 (0.15) -Orthopaedic shoe: 0.37 (0.21)	poor
Tomioka (2017)[3 1]			Chronic	4 weeks training with an AFO	-RAFO (n:1) -PLS-AFO(n:2) -Hinged AFO (n: 24)	- TUG (s)	- No AFO before training: 0.68 (0.22) -After training with AFO: 0.81 (0.24)	poor
2013)[45	Non- clinical trial (quasi- experimental	24 individuals (M:16, F:8) with chronic stroke, could ambulate at least 10 m with or without an assistive device, mean age:57years, mean time from stroke: 6.4 months, MAS: nr, FAC ≥4	Chronic	12 weeks	A conventional non-articulated AFO	-Rivermead Mobility Index (score)	-No AFO before training: 0.36 (0.26) -No AFO after training:	good
							-With AFO after training:	

							0.55(0.33)	
. ,	Non- randomized, parallel-group	32 individuals (18 Non-users, 14 AFO users) with chronic stroke, able to walk 5 minutes without assistance. -Non-users: 18 (M:12, F:6) mean age:54.8years, MAS for soleus: 0.3±0.5 -AFO users: 14 (M:7, F:7), mean age:54.7years, MAS for soleus: 1.0±1.0	Chronic	At least one month	PLS-AFO	-BBS (score)	-No AFO:1.03 (0.30) -With AFO: 0.96 (0.49)	fair

\* Mean walking speed was calculated and estimated using other clinical tests, such as 10-meter walking test (10MWT) and 5-meter walking test (5MWT) because it was not directly reported.

6MWT: 6-Minute Walking Test, AFO: ankle-foot orthosis, AAFO: anterior AFO, AFO-PS: hinged plastic or metal AFO with plantarflexion stop and dorsiflexion free, BS: Brunnstrom stage, BBS: Berg Balance Scale, CAFO: carbon fiber AFO, CG: control group, DA: metal double action joints and metal upright, DAFO: dynamic AFO, F: female, FAC: Functional Ambulatory Categories, FIM: Functional Independence Measure, FRT: Functional Reach Test, PAFO: plastic ankle-foot orthosis, PLS-AFO: posterior leaf spring AFO, PWS: preferred walking speed, M: men, MAS: Modified Ashworth Scale, mEFAP: modified Emory Functional Ambulation Profile, nr: not reported, RAFO: rigid AFO, RS: rocker shoe, SG: study group, SS: standard shoe, TDS: Timed Down-Stairs, TS: Tardieu scale(this sale measures the degree of spasticity), TUG: Timed-Up and Go Test, TUS: Timed Up Stairs,

#### **Figure legends**

**Figure 1**. Flowchart of the articles selection using the PRISMA. AFO: ankle-foot orthosis, FES: functional electrical stimulation

**Figure 2**. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Berg Balance Scale (a) and Timed Up and Go Test (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for Berg Balance Scale is toward positive values and for Timed Up and Go Test is toward negative values

**Figure 3**. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Functional Ambulation Categories (a) and 6-Minute Walking Test (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for both tests is toward positive values

**Figure 4**. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Timed Up-Stairs (a) and Motricity Index (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for Timed Up-Stairs is toward negative values and for Motricity Index is toward positive values




Figure 1. Flowchart of the articles selection using the PRISMA. AFO: ankle-foot orthosis, FES: functional electrical stimulation

Screening

Eligibility

Included




Figure 2. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Berg Balance Scale (a) and Timed Up and Go Test (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for Berg Balance Scale is toward positive values and for Timed Up and Go Test is toward negative values

ID	with AFO	without AFO	SMD (95% CI)	Weię
Erel 2011			-0.46 (-1.21, 0.29)	6.61
Simons 2009		<u>_</u> +	-0.50 (-1.13, 0.13)	8.65
Doggan 2011		•	-0.28 (-0.67, 0.11)	15.7
Pavlik 2008		•	-0.18 (-1.57, 1.21)	2.26
de Wit 2004		•	-0.29 (-0.92, 0.33)	8.79
Pardo 2015	•	-	-1.06 (-1.86, -0.27)	6.04
Pardo 2015	•	-	-1.12 (-1.92, -0.32)	5.97
Nikamp 2017 (follow-up <3 months, early group)		•	-0.26 (-1.18, 0.66)	4.71
Nikamp 2017 (follow-up <3 months, delayed group)	—— <u> </u>	•	-0.13 (-1.03, 0.76)	4.95
Nikamp 2017 (follow-up 6-month, early group)		<u> </u>	-0.84 (-1.79, 0.10)	4.51
Nikamp 2017 (follow-up 6-month, delayed group)	•		-0.55 (-1.46, 0.36)	4.80
Hale 2013			-0.77 (-2.07, 0.53)	2.58
Sheffler 2006			-0.71 (-1.45, 0.03)	6.78
Tomloka 2017			-0.66 (-1.21, -0.11)	10.5
Nevisipour 2019	_		0.66 (-0.06, 1.38)	7.10
Overall (I-squared = 21.7%, p = 0.212)	$\Leftrightarrow$	>	-0.45 (-0.67, -0.24)	100.
NOTE: Weights are from random effects analysis				





Figure 3. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Functional Ambulation Categories (a) and 6-Minute Walking Test (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for both tests is toward positive values






Figure 4. Overall pooled SMD by random-effects model for an AFO versus without an AFO on Timed Up-Stairs (a) and Motricity Index (b). AFO: ankle-foot orthosis, SMD: standardized mean difference. The direction of improvement for Timed Up-Stairs is toward negative values and for Motricity Index is toward positive values

Study (b)				%
ID			SMD (95% CI)	Weight
	without AFO	with AFO		
Nikamp 2017 (follow-up <3 months, early group)		••••	0.27 (-0.42, 0.97)	15.08
Nikamp 2017 (follow-up <3 months, delayed group)			0.90 (0.13, 1.68)	12.11
Nikamp 2017 (follow-up 6-month, early group)			1.00 (0.23, 1.76)	12.55
Nikamp 2017 (follow-up 6-month, delayed group)			1.20 (0.40, 2.01)	11.28
de Sèze 2011 (Chignon group, follow-up <3 months)			0.45 (-0.33, 1.23)	12.05
de Sèze 2011 (Chignon group,follow-up >3 months)	_		0.51 (-0.29, 1.31)	11.48
de Sèze 2011 (AFO-PLS group, follow-up <3 months)		-	0.36 (-0.36, 1.08)	14.04
de Sèze 2011 (AFO-PLS group, follow-up >3 months)	_		0.67 (-0.13, 1.47)	11.41
Overall (I-squared = 0.0%, p = 0.645)		$\diamond$	0.65 (0.38, 0.92)	100.00
NOTE: Weights are from random effects analysis				
-2.01	(	)	2.01	

# Implications for rehabilitation

- An AFO can improve functional performance and ambulation in survivors of strokes
- Wearing an AFO in rehabilitation care during the subacute phase post stroke may have beneficial effects on functional outcomes measured.
- There was no evidence as to the effectiveness of specific AFO designs over others.

#### **Supplementary Material**

### **Supplemental Appendix 1: Search strategies**

#### Search strategy for PubMed

(((((("cerebrovascular") OR "CVA") OR "stroke") OR hemi\*)) AND ((((orthos\*) OR "brace") OR "orthotic") OR "caliper")) AND ((((((((((((((((((stair") OR "ambulatory function") OR "functional ambulation") OR "walking ability") OR "walking capacity") OR "TUG") OR "functional ambulation") OR "six minute") OR "6 minute") OR "6MWT") OR "Functional Reach") OR "Motricity Index") OR "Emory") OR "Barthel Index") OR "Rivermead Mobility Index") OR "Berg Balance Scale") OR "balance") OR "Functional Ambulation Categories") OR "Functional Independence Measure") OR "Spasticity") OR "walking") OR "Step Test") OR "mobility")

#### Search strategy for Scopus

(ALL("stroke") OR ALL("cerebrovascular") OR ALL(hemi\*) OR ALL("CVA")) AND (ALL("orthotic") OR ALL(orthos\*) OR ALL("AFO") OR ALL("brace") OR ALL("caliper") OR ALL("orthotic device")) AND (ALL("mobility") OR ALL("stair") OR ALL("ambulatory function") OR ALL("walking ability") OR ALL("walking capacity") OR ALL("TUG") OR ALL("Timed Up and Go") OR ALL("6 minute") OR ALL("six minute") OR ALL("6MWT") OR ALL("Functional Reach") OR ALL("Motricity Index") OR ALL("Rivermead Mobility Index") OR ALL("Emory") OR ALL("Berg Balance Scale") OR ALL("Functional Ambulation Categories") OR ALL("step test") OR ALL("walking") OR ALL("balance") OR ALL("Functional Independence Measure"))

#### Search strategy for Web of Science

(TS=("stroke") OR TS=("cerebrovascular") OR TS=(hemi\*) OR TS=("CVA")) AND (TS=("orthotic") OR TS=(orthos\*) OR TS=("AFO") OR TS=("brace") OR TS=("caliper") OR TS=("orthotic device")) AND (TS=("mobility") OR TS=("stair") OR TS=("ambulatory function") OR TS=("walking ability") OR TS=("TUG") OR TS=("Timed Up and Go") OR TS=("6 minute") OR TS=("six minute") OR TS=("6MWT") OR TS=("Functional Reach") OR TS=("Motricity Index") OR TS=("Rivermead Mobility Index") OR TS=("Barthel Index") OR TS=("Emory") OR TS=("Berg Balance Scale") OR TS=("Functional Ambulation Categories") OR TS=("Step Test ") OR TS=("Functional Independence Measure") OR TS=( step test) OR TS=(balance) OR TS=(walking) OR TS=(Spasticity))

#### Search strategy for Embase

('cerebrovascular disease'/exp OR stroke OR 'hemiplegia'/exp OR 'hemiparesis'/exp OR hemiparetic) AND ('brace'/exp OR 'orthosis'/exp OR 'orthotics'/exp OR 'ankle foot OR orthoses OR 'orthotic orthosis'/exp OR 'caliper'/exp device') AND (mobility OR stair OR 'ambulatory function' OR 'walking ability' OR 'timed up and go test/exp OR 'six minute walk test'/exp OR 'functional reach'/exp OR 'motricity index'/exp OR emory OR 'berg balance scale'/exp OR 'functional ambulation categories' OR 'step test'/exp OR 'functional independence measure'/exp OR 'spasticity'/exp OR 'rivermead mobility index'/exp OR 'barthel index'/exp)

#### ProQuest

("Stroke" OR "Cerebrovascular" OR "hemiplegia" OR "hemiparetic" OR "hemiparesis") AND ("Brace" OR "Orthotic Device" OR "orthosis" OR "orthoses" OR "Orthotic" OR "caliper") AND ("mobility" OR "stair" OR "ambulatory function" OR "walking ability" OR "walking capacity" OR "TUG" OR "Timed Up and Go" OR "6MWT" OR "six minute" OR "6 minute" OR "Functional Reach" OR "Berg Balance Scale" OR "Functional Ambulation Categories" OR "Step Test" OR "Functional Independence Measure" OR "Motricity Index" OR "Rivermead Mobility Index" OR "Barthel Index" OR "balance" OR "walking" OR "Spasticity")

#### Search strategy for Cochrane Central

(Stroke OR Cerebrovascular OR hemiplegia OR hemiparesis OR hemiparetic) AND (Brace OR Orthotic Device OR orthosis OR orthoses OR Orthotic OR caliper) AND (mobility OR stair OR ambulatory function OR walking ability OR walking capacity OR TUG OR Timed Up and Go OR 6MWT OR six minute OR 6 minute OR Functional Reach OR Motricity Index OR Berg

Balance Scale OR Functional Ambulation Categories OR Step Test OR Functional Independence Measure OR Motricity Index OR Rivermead Mobility Index OR Barthel Index OR balance OR walking OR Spasticity)

Author (year)	Title	Reason for exclusion
Chen (2014)	Effects of an Anterior Ankle-Foot Orthosis on Walking Mobility in Stroke Patients: Get Up and Go and Stair Walking	Observational study (Retrospective)
Hung (2011)	Long-Term Effect of an Anterior Ankle-Foot Orthosis on Functional Walking Ability of Chronic Stroke Patients	Observational study (Retrospective)
Nolan (2009)	Objective Assessment of Functional Ambulation in Adults with Hemiplegia using Ankle Foot Orthotics after Stroke	Observational study (Retrospective)
BouchaloVá1 (2016)	The influence of an ankle-foot orthosis on the spatiotemporal gait parameters and functional balance in chronic stroke patients	Observational study (Retrospective)
Maeshima (2017)	Lower Limb Orthotic Therapy for Stroke Patients in a Rehabilitation Hospital and Walking Ability at Discharge	Observational study (Retrospective)
Ota (2018)	Difference in independent mobility improvement from admission to discharge between subacute stroke patients using knee-ankle-foot and those using ankle-foot orthoses	Observational study (Retrospective)
Kesikburun (2017)	Effect of ankle foot orthosis on gait parameters and functional ambulation in patients with stroke	Observational study (Retrospective)
Ota (2018)	Differences in activities of daily living between people with subacute stroke who received knee-ankle-foot and ankle-foot orthoses at admission	Observational study (Retrospective)
Teasell (2001)	Physical and Functional Correlations of Ankle-Foot Orthosis Use in the Rehabilitation of Stroke Patients	Observational study (Retrospective)
Shen (2013)	Early application of front-ankle-foot orthosis affects the walking ability and speed of the patients with hemiplegia after stroke	Observational study (Retrospective)
MURAGUCHI (2013)	The Effect of a Plastic Ankle Foot Orthosis on the Balance and Walking Ability of Community-dwelling Individuals with Chronic Stroke.	Observational study (Retrospective)
Xu (2011)	Effects of Ankle-Foot Orthosis on Gait Stability and Balance Control in Patients With Hemiparetic Stroke	Observational study (Retrospective)
Bregman(2010)	Polypropylene ankle foot orthoses to overcome drop-foot gait in central neurological patients: a mechanical and functional evaluation.	Population (stroke and multiple sclerosis)
DeMeyer (2015)	Effectiveness of a night positioning programme on ankle range of motion in patients after hemiparesis: a prospective randomized controlled pilot study	Population (stroke and brain injury)
McCain (2012)	Ankle-Foot Orthosis Selection to Facilitate Gait Recovery in Adults After Stroke: A Case Series	Values for 6MWT were not reported
Beatrice Janka	Relative influence of orthotic support features within an open frame AFO versus a total contact AFO on function, endurance, and activity level in patients with spastic equinovarus secondary to chronic stroke	Number of patients and values for 6MWT were not reported
Nikamp (2019)	The effect of ankle-foot orthoses on fall/near fall incidence in patients with (sub-)acute stroke: A randomized controlled trial	Duplicated data
Maguire (2012)	How to improve walking, balance and social participation following stroke: a comparison of the long term effects of two walking aids canes and an orthosis TheraTogson the recovery of gait following	Used orthosis was not an AFO

# Supplemental Appendix 2: List of excluded papers


		r
	acute stroke. A study protocol for a multi-centre, single blind, randomised control trial	
Schiemanck(2015)	.Effects of implantable peroneal nerve stimulation on gait quality, energy expenditure, participation and user satisfaction in patients with post-stroke drop foot using an ankle-foot orthosis	Used robotic or FE orthoses
Schiemanck(2015)	peroneal nerve stimulation on gait quality, energy expenditure, participation and user satisfaction in patients with post-stroke drop foot using an ankle-foot orthosis	Used robotic or FE orthoses
Hesse (2012)	Robot-assisted practice of gait and stair climbing in nonambulatory stroke patients	Used robotic or FE orthoses
Rahman(2014)	Asymmetrical Performance and Abnormal Synergies of the Post- Stroke Patient Wearing SCRIPT Passive Orthosis in Calibration, Exercise and Energy Evaluation	Used robotic or FE orthoses
Maeshima(2011)	Efficacy of a hybrid assistive limb in post-stroke hemiplegic patients: a preliminary report	Used robotic or FE orthoses
Ward(2011)	Stroke Survivors' Gait Adaptations to a Powered Ankle Foot Orthosis.	Used robotic or FE orthoses
Stein(2010)	Long-term therapeutic and orthotic effects of a foot drop stimulator on walking performance in progressive and nonprogressive neurological disorders.	Used robotic or FE orthoses
Krewer (2007)	The influence of different Lokomat walking conditions on the energy expenditure of hemiparetic patients and healthy subjects	Used robotic or FE orthoses
Geroin (2011)	Combined transcranial direct current stimulation and robot-assisted gait training in patients with chronic stroke: a preliminary comparison	Used robotic or FE orthoses
Rao (2014)	The Effects of Two Different Ankle-Foot Orthoses on Gait of Patients with Acute Hemiparetic Cerebrovascular Accident	No functional outcome
Do (2014)	Effect of a Hybrid Ankle Foot Orthosis Made of Polypropylene and Fabric in Chronic Hemiparetic Stroke Patients	No functional outcome
Beckerman (1996)	Walking Ability of Stroke Patients: Efficacy of Tibia1 Nerve Blocking and a Polypropylene Ankle-Foot Orthosis	No functional outcome
Tyson (2018)	Bespoke versus off-the-shelf ankle-foot orthosis for people with stroke	No functional outcome
Zissimopoulos(2014)	The effect of ankle–foot orthoses on self-reported balance confidence in persons with chronic poststroke hemiplegia	No functional outcome
Iwata (2003)	An Ankle-Foot Orthosis With Inhibitor Bar: Effect on Hemiplegic Gait	No functional outcome
Kobayashi(2015)	The effect of changing plantarflexion resistive moment of an articulated ankle–foot orthosis on ankle and knee joint angles and moments while walking in patients post stroke	No functional outcome
Lewallen (2010)	Effect of three styles of custom ankle foot orthoses on the gait of stroke patients while walking on level and inclined surfaces	No functional outcome
Mehan (2012)	A preliminary study into the immediate effects of ankle foot orthoses of varying design on the walking of people in the early stages of stroke recovery and healthy individuals	No functional outcome
Yamamoto(2011)	Change of rocker function in the gait of stroke patients using an ankle foot orthosis with an oil damper: immediate changes and the short- term effects	No functional outcome
Akezaki (2016)	The Physical Function of Stroke Patients Necessary for an Independent Gait with the Use of an Ankle Foot Orthosis	No functional outcome
CUI(2008)	The effect of ankle-foot orthoses on motor function of the lower extremities about 40 cases of hemiplegic stroke patients	No functional outcome
Kim (2015)	Effect of ankle-foot orthosis on weight bearing of chronic stroke patients performing various functional standing tasks	No functional outcome
Bae (2019)	Effects of dorsiflexor functional electrical stimulation compared to an ankle/foot orthosis on stroke-related genu recurvatum gait	No functional outcome

Bulley (2011)	User experiences, preferences and choices relating to functional	No functional
-	electrical stimulation and ankle foot orthoses for foot-drop after stroke Effect of Ankle-foot Orthosis on Lower Limb Muscle Activities and	outcome No functional
Lee (2014)	Static Balance of Stroke Patients Authors' Names	
	Static Balance of Stroke Patients Authors Tvalles Static ankle-foot orthosis improves static balance and gait functions in	Outcome No functional
Chern (2013)	hemiplegic patients after stroke	outcome
	Effects of ankle-foot orthoses on mediolateral foot-placement ability	No functional
Zissimopoulos (2014)	during post-stroke gait	
	Immediate Effects of Ankle–Foot Orthosis Using Wire on Static	No functional
Lee (2020)		
	Balance of Patients with Stroke with Foot Drop: A Cross-Over Study	outcome
Uutela (2003)	The effect of dynamic ankle-foot orthoses on the balance and gait of	No functional
	stroke patients	Outcome
Chang (2007)	The effects of anterior and posterior ankle-foot-orthosis on postural	No functional
	stability in stroke patients	outcome
Bleyenheuft(2008)	Assessment of the Chignon dynamic ankle-foot orthosis using	No functional
• • •	instrumented gait analysis in hemiparetic adults	outcome
MULROY (2010)	Effect of AFO design on walking after stroke: Impact of ankle plantar	No functional
× ,	flexion contracture	outcome
Gök(2003)	Effects of ankle-foot orthoses on hemiparetic gait	No functional
~ - /		outcome
Do KH (2014)	Effect of a Hybrid Ankle Foot Orthosis Made of Polypropylene and	No functional
(	Fabric in Chronic Hemiparetic Stroke Patients	outcome
Fatone (2009)	Effect of Ankle-Foot Orthosis Alignment and Foot-Plate Length on	No functional
	the Gait of Adults With Poststroke Hemiplegia	outcome
Zollo (2015)	Comparative analysis and quantitative evaluation of ankle-foot	No functional
2010 (2015)	orthoses for foot drop in chronic hemiparetic patients	outcome
Park (2009)	Comparison of Gait Analysis Between Anterior and Posterior Ankle	No functional
1 un (2007)	Foot Orthosis in Hemiplegic Patients	outcome
Lairamore (2011)	Comparison of tibialis anterior muscle electromyography, ankle angle,	No functional
2011)	and velocity when individuals post stroke walk with different orthoses	outcome
	Comparison of ankle-foot orthoses with plantar flexion stop and	No functional
Yamamoto (2018)	plantar flexion resistance in the gait of stroke patients: A randomized	outcome
	controlled trial	outcome
	The effect of changing plantarflexion resistive moment of an	No functional
Kobayashi (2015)	articulated ankle-foot orthosis on ankle and knee joint angles and	
	moments while walking in patients post stroke	outcome
	Reduction of genu recurvatum through adjustment of plantarflexion	No functional
Kobayashi (2016)	resistance of an articulated ankle-foot orthosis in individuals post-	
	stroke	outcome
$E_{atoma}$ (2007)	Effect of ankle-foot orthosis on roll-over shape in adults with	No functional
Fatone (2007)	hemiplegia	outcome
$L_{20}(2019)$	A novel hinged ankle foot orthosis for gait performance in chronic	No functional
Lee(2018)	hemiplegic stroke survivors: a feasibility study	outcome
	An articulated ankle-foot orthosis with adjustable plantarflexion	No franction 1
Kobayashi(2017)	resistance, dorsiflexion resistance and alignment: A pilot study on	No functional
- · · ·	mechanical properties and effects on stroke hemiparetic gait	outcome
	An investigation of the neurophysiologic effect of tone-reducing	
Ibuki (2010)	AFOs on reflex excitability in subjects with spasticity	No functional
` '	following stroke while standing	outcome
<b>a</b> ( <b>1</b> )	Kinematic features of rear-foot motion using anterior and posterior	No functional
Chen (2010)	ankle-foot orthoses in stroke patients with hemiplegic gait	outcome
	Design and Evaluation of an Articulated Ankle Foot Orthosis with	
Daryabor (2019)	Plantarflexion Resistance on the Gait: a Case Series of 2 Patients with	No functional
Darya001 (2017)	Hemiplegia	outcome
Farmani (2019)	The Influence of Rocker Bar Ankle Foot Orthosis on Gait in Patients	No functional
1°annani (2019)	The minucine of Nouvel Dat Alikie Foot Offiosis off Galt III Patients	no functional


	with Chronic Hemiplegia	outcome
Hesse (1996)	Gait function in spastic hemiparetic patients walking barefoot, with	No functional
110350 (1990)	firm shoes, and with ankle-foot orthosis	outcome
Hesse (1999)	Gait function in spastic hemiparetic patients walking barefoot, with	No functional
Tiesse (1999)	firm shoes, and with ankle-foot orthosis	outcome
Jagadamma (2010)	The effects of tuning an ankle-foot orthosis footwear combination on	No functional
Jagadallilla (2010)	kinematics and kinetics of the knee joint of an adult with hemiplegia	outcome
Nolan (2011)	Weight transfer analysis in adults with hemiplegia using ankle foot	No functional
Notali (2011)	orthosis	outcome
Nolan (2011)	Preservation of the first rocker is related to increases in gait speed in	No functional
Notali (2011)	individuals with hemiplegia and AFO	outcome
Obsta $(2011)$	Effects of an ankle-foot orthosis with oil damper on muscle activity in	No functional
Ohata (2011)	adults after stroke	outcome
	The effect of ankle-foot orthosis plantarflexion stiffness on ankle and	No functional
Singer (2014)	knee joint kinematics and kinetics during first and second rockers of	
	gait in individuals with stroke	outcome
Wang (2007)	Gait and balance performance improvements attributable to ankle-	No functional
walig (2007)	foot orthosis in subjects with hemiparesis	outcome
$V_{amamata}(2015)$	Immediate-term effects of use of an ankle-foot orthosis with an oil	No functional
Yamamoto (2015)	damper on the gait of stroke patients when walking without the device	outcome
Vamamata (2015)	Effects of plantar flexion resistive moment generated by an ankle-foot	No functional
Yamamoto (2015)	orthosis with an oil damper on the gait of stroke patients: a pilot study	outcome


•

**Supplemental Figure 1.** Subgroup analysis by random-effects model for an AFO versus without an AFO on Berg Balance Scale: a) stroke phase, b) adaptation time, c) quality status, d) walking speed. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for Berg Balance Scale is toward positive values.




Study (b) ID	without AFO	with AFO	SMD (95% CI)	% Weigh
> 3 months				
Simons 2009	_		0.37 (-0.26, 0.99)	9.23
Nikamp 2017 (follow-up 6-month, early group)			2.19 (1.25, 3.12)	
Nikamp 2017 (follow-up 6-month, delayed group)			1.16 (0.35, 1.96)	
Subtotal (I-squared = 80.5%, p = 0.006)			1.19 (0.17, 2.21)	
			,	
< 3 months				
Doggan 2011			0.70 (0.30, 1.10)	11.27
Nikamp 2017 (follow-up <3 months, early group)			0.97 (0.23, 1.72)	
Nikamp 2017 (follow-up <3 months, delayed group)			0.98 (0.19, 1.76)	
Yue 2013			-0.21 (-0.95, 0.53)	8.20
Cakar 2010	_		0.64 (0.06, 1.22)	9.64
Nevisipour 2019		<b>—</b> [	-0.29 (-0.99, 0.41)	8.55
Subtotal (I-squared = 59.7%, p = 0.029)	_	$\diamond$	0.48 (0.07, 0.89)	53.67
		<b>1</b>		
immediate				
Wang 2005 (short-duration stroke)	-	<b>-</b>	0.00 (-0.43, 0.43)	11.03
Wang 2005 (long-duration stroke)	-	-	0.10 (-0.26, 0.46)	11.65
Subtotal (I-squared = 0.0%, p = 0.724)	<	$\overline{\mathbf{b}}$	0.06 (-0.21, 0.33)	22.68
Overall (I-squared = 72.9%, p = 0.000)		$\diamond$	0.54 (0.19, 0.88)	100.0
NOTE: Weights are from random effects analysis				
-3.12	c	)	3.12	







**Supplemental Figure 2.** Subgroup analysis by random-effects model for an AFO versus without an AFO on Timed Up and Go Test: a) stroke phase, b) AFO type, c) adaptation time, d) quality status, e) walking speed. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for Timed Up and Go Test is toward negative values



ID	with AFO	without AFO	SMD (95% CI)	Weig
non-articulated				
Erel 2011	· · · · · · · · · · · · · · · · · · ·	<u> </u>	-0.46 (-1.21, 0.29)	6.61
de Wit 2004			-0.29 (-0.92, 0.33)	8.79
Nikamp 2017 (follow-up <3 months, early group)			-0.26 (-1.18, 0.66)	4.71
Nikamp 2017 (follow-up <3 months, delayed group)			-0.13 (-1.03, 0.76)	4.95
Nikamp 2017 (follow-up 6-month, early group)		-	-0.84 (-1.79, 0.10)	4.51
Nikamp 2017 (follow-up 6-month, delayed group)			-0.55 (-1.46, 0.36)	4.80
Hale 2013			-0.77 (-2.07, 0.53)	2.58
Nevisipour 2019		•	0.66 (-0.06, 1.38)	7.10
Subtotal (I-squared = 23.0%, p = 0.246)	$\leftarrow$	-	-0.26 (-0.60, 0.08)	44.0
mixed				
Simons 2009	-	<b>-</b>	-0.50 (-1.13, 0.13)	8.65
Pavlik 2008			-0.18 (-1.57, 1.21)	2.26
Sheffler 2006		ł	-0.71 (-1.45, 0.03)	6.78
Tomioka 2017			-0.66 (-1.21, -0.11)	10.5
Subtotal (I-squared = 0.0%, p = 0.900)	$\langle \rangle$		-0.59 (-0.94, -0.24)	28.2
articulated				
Doggan 2011	•	-	-0.28 (-0.67, 0.11)	15.7
Pardo 2015			-1.06 (-1.86, -0.27)	6.04
Pardo 2015			-1.12 (-1.92, -0.32)	5.97
Subtotal (I-squared = 62.5%, p = 0.070)			-0.74 (-1.35, -0.12)	27.7
Overall (I-squared = 21.7%, p = 0.212)	$\Leftrightarrow$		-0.45 (-0.67, -0.24)	100.
NOTE: Weights are from random effects analysis				




Study (d) ID	With AFO	Mitheut A EQ	SMD (95% CI)	% Weig
		Without AFO		
fair	<u>i</u>			
Erel 2011			-0.46 (-1.21, 0.29)	6.61
Doggan 2011		•++	-0.28 (-0.67, 0.11)	15.74
de Wit 2004		<b></b>	-0.29 (-0.92, 0.33)	8.79
Sheffler 2006	- <b>-</b>	<b>→</b> _	-071 (-1.45, 0.03)	6.78
Nevisipour 2019			0.66 (-0.06, 1.38)	7.10
Subtotal (I-squared = 50.1%, p = 0.091)	<	$\rightarrow$	-0.22 (-0.62, 0.17)	45.01
		-		
poar	L .			
Simans 2009		<del></del>	-0.50 (-1.13, 0.13)	8.65
Pavlik 2008			-0.18 (-1.57, 1.21)	2.26
Pardo 2015	-	-	-1.06 (-1.86, -0.27)	6.04
Pardo 2015 -			-1.12 (-1.92, -0.32)	5.97
Hale 2013		<u> </u>	-077 (-2.07, 0.53)	2.58
Tomioka 2017			-0.66 (-1.21, -0.11)	10.51
Subtotal (I-squared = 0.0%, p = 0.737)	$\sim$		-0.74 (-1.05, -0.42)	36.01
good				
Nikamp 2017 (follow-up <3 months, early group)		•	-0.26 (-1.18, 0.66)	4.71
Nikamp 2017 (follow-up <3 months, delayed group)			-0.13 (-1.03, 0.76)	4.95
Nikamp 2017 (follow-up 6-month, early group)		<b>—</b>	-0.84 (-1.79, 0.10)	4.51
Nikamp 2017 (follow-up 6-month, delayed group)		<u> </u>	-0.55 (-1.46, 0.36)	4.80
Subtotal (I-squared = 0.0%, p = 0.717)		>	-0.44 (-0.90, 0.02)	18.98
	T			
Overall (I-squared = 21.7%, p = 0.212)	$\diamond$	>	-0.45 (-0.67, -0.24)	100.0
NOTE: Weightsare from random effects analysis	Ī			
	I			_
-2.07		0	207	




**Supplemental Figure 3.** Subgroup analysis by random-effects model for an AFO versus without an AFO on Functional Ambulation Categories: a) stroke phase, b) AFO type, c) adaptation time, d) quality status. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for Functional Ambulation Categories is toward negative values.


Study (a) ID	without AFO	with AFO	SMD (95% CI)	% Weig
chronic				
Simons 2009			1.27 (0.59, 1.95)	7.80
Abe 2009			1.99 (1.13, 2.85)	7.13
Subtotal (I-squared = 40.3%, p = 0.196)		$\diamond$	1.58 (0.88, 2.28)	14.93
subacute				
Tyson 2009			4.34 (3.19, 5.50)	5.97
Nikamp 2017 (follow-up <3 months, early group)		-	1.00 (0.26, 1.74)	7.59
Nikamp 2017 (follow-up <3 months , delayed group)			2.06 (1.14, 2.98)	6.88
Nikamp 2017 (follow-up 6-month, early group)			2.97 (1.91, 4.02)	6.34
Nikamp 2017 (follow-up 6-month, delayed group)			2.19 (1.24, 3.13)	6.79
de Sèze 2011 (Chignon group, follow-up <3 months)			1.12 (0.29, 1.95)	7.23
de Sèze 2011 (Chignon group, follow-up >3 months)			1.19 (0.33, 2.04)	7.13
de Sèze 2011 (AFO-PLS group, follow-up ≺3 months)			1.62 (0.79, 2.45)	7.22
de Sèze 2011 (AFO-PLS group, follow-up >3 months)		_ <del>``≡</del>	2.21 (1.21, 3.20)	6.57
Yue 2013		<u>+∎</u> ¦	0.39 (-0.36, 1.14)	7.55
Subtotal (I-squared = 80.7%, p = 0.000)			1.85 (1.21, 2.49)	69.27
		1		
mixed				
Tyson 2001			2.03 (1.35, 2.72)	7.78
Assawapalangchai 2017		- <b>B</b> -	0.63 (0.01, 1.25)	8.03
Subtotal (I-squared = 88.7%, p = 0.003)		$\sim$	1.32 (-0.05, 2.70)	15.81
Overall (I-squared = 78.0%, p = 0.000)			1.72 (1.25, 2.19)	100.0
NOTE: Weights are from random effects a nalysis				

study (b) ID	without AFO	with AFO	SMD (95% CI)	% Weigh
mixed				
Simons 2009			1.27 (0.59, 1.95)	7.80
Abe 2009			1.99 (1.13, 2.85)	7.13
Subtotal (I-squared = 40.3%, p = 0.196)		$\diamond$	1.58 (0.88, 2.28)	14.93
non-articulated				
Tyson 2009		I I —	4.34 (3.19, 5.50)	5.97
Nikamp 2017 (follow-up <3 months, early group)			1.00 (0.26, 1.74)	7.59
Nikamp 2017 (follow-up <3 months , delayed group)			2.06 (1.14, 2.98)	6.88
Nikamp 2017 (follow-up 6-month, early group)			2.97 (1.91, 4.02)	6.34
Nikamp 2017 (follow-up 6-month, delayed group)			2.19 (1.24, 3.13)	6.79
Assawapalangchai 2017			0.63 (0.01, 1.25)	8.03
de Sèze 2011 (AFO-PLS group, follow-up <3 months)			1.62 (0.79, 2.45)	7.22
de Sèze 2011 (AFO-PLS group, follow-up >3 months)		-	2.21 (1.21, 3.20)	6.57
Yue 2013	-		0.39 (-0.36, 1.14)	7.55
Subtotal (I-squared = 85.1%, p = 0.000)			1.87 (1.13, 2.61)	62.94
articulated				
Tyson 2001			2.03 (1.35, 2.72)	7.78
de Sèze 2011 (Chignon group, follow-up <3 months)			1.12 (0.29, 1.95)	7.23
de Sèze 2011 (Chignon group,follow-up >3 months)			1.19 (0.33, 2.04)	7.13
Subtotal (I-squared = 44.9%, p = 0.163)		$\diamond$	1.49 (0.88, 2.10)	22.13
Overall (I-squared = 78.0%, p = 0.000)		$\diamond$	1.72 (1.25, 2.19)	100.0
NOTE: Weights are from random effects analysis				
-5.5		0	5.5	






**Supplemental Figure 4.** Subgroup analysis by random-effects model for an AFO versus without an AFO on 6-Minute Walking Test: a) stroke phase, b) adaptation time, c) quality status, d) walking speed. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for 6-Minute Walking Test is toward positive values.





	without AFO	with AFO	SMD (95% CI) Weight
mmediate			
lyun 2005			0.33 (-0.39, 1.05)16.58
lale 2013		-	0.96 (-0.37, 2.29)6.78
Subtotal (I-squared = 0.0%, p = 0.412)	-	$ \rightarrow $	0.47 (-0.16, 1.11)23.36
· 3 months			
Maeda 2009	-		0.47 (-0.20, 1.13)18.30
likamp 2017(follow-up >6-month, early group)			1.70 (0.86, 2.55) 13.52
likamp 2017(follow-up >6-month, delayed group)			1.45 (0.59, 2.30) 13.31
Subtotal (I-squared = 67.3%, p = 0.047)		$\langle \rangle$	1.17 (0.38, 1.96) 45.13
< 3 months			
likamp 2017(follow-up <3 months, early group)			0.83 (0.11, 1.56) 16.49
likamp 2017(follow-up <3 months, delayed group)			0.94 (0.16, 1.72) 15.02
Subtotal (I-squared = 0.0%, p = 0.845)			0.88 (0.35, 1.41) 31.51
Overall (I-squared = 34.4%, p = 0.165)		$\diamond$	0.91 (0.53, 1.28) 100.00
OTE: Weights are from random effects analysis			
-2.55		0	2.55




Study (d) ID	without AFO	with AFO	SMD (95% CI)	% Weigh
limited community				
Hyun 2005	_		0.33 (-0.39, 1.05)	) 16.58
Hale 2013	_	-	0.96 (-0.37, 2.29)	6.78
Subtotal (I-squared = 0.0%, p = 0.412)		$\langle \rangle$	0.47 (-0.16, 1.11)	23.36
household				
Maeda 2009	-		0.47 (-0.20, 1.13)	18.30
Nikamp 2017(follow-up <3 months, early group)			0.83 (0.11, 1.56)	16.49
Nikamp 2017(follow-up <3 months, delayed group)			0.94 (0.16, 1.72)	15.02
Nikamp 2017(follow-up >6-month, early group)			1.70 (0.86, 2.55)	13.52
Nikamp 2017(follow-up >6-month, delayed group)			1.45 (0.59, 2.30)	13.31
Subtotal (I-squared = 38.0%, p = 0.168)			1.03 (0.59, 1.46)	76.64
Overall (I-squared = 34.4%, p = 0.165)			0.91 (0.53, 1.28)	100.00
NOTE: Weights are from random effects analysis				
-2.55		0	2.55	

**Supplemental Figure 5.** Subgroup analysis by random-effects model for an AFO versus without an AFO on Timed Up-Stairs: a) stroke phase, b) adaptation time, c) quality status, d) walking speed. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for Timed Up-Stairs is toward negative values.






with AFO	without AFO	SMD (95% CI)	Weight
	<del> </del>	-0.34 (-1.08, 0.41)	12.91
	<b></b>	-0.21 (-0.83, 0.41)	17.28
$\Diamond$	>	-0.26 (-0.74, 0.22)	30.19
_	L		
÷	•—	-0.04 (-0.43, 0.35)	32.40
	<b>—</b>	-0.62 (-1.66, 0.42)	7.30
	<u>*</u>	0.00 (-1.20, 1.20)	5.60
•		-1.46 (-2.54, -0.37)	6.74
	<u> </u>	-0.26 (-1.46, 0.95)	5.55
	-	-0.80 (-1.57, -0.02)	12.22
$\diamond$		-0.46 (-0.91, -0.01)	69.81
$\diamond$	•	-0.35 (-0.64, -0.05)	100.00
			-0.26 (-0.74, 022) -0.26 (-0.74, 022) -0.04 (-0.43, 0.35) -0.62 (-1.66, 0.42) 000 (-1.20, 1.20) -1.46 (-2.54, -0.37) -0.26 (-1.46, 0.95) -0.80 (-1.57, -0.02) -0.46 (-0.91, -0.01)





**Supplemental Figure 6.** Subgroup analysis by random-effects model for an AFO versus without an AFO on Motricity Index: a) adaptation time, b) quality status. AFO: Ankle-Foot Orthosis, SMD: Standardized Mean Difference. The direction of improvement for Motricity Index is toward positive values.

Study (b)			SMD (95% CI)	% Weight
	without AFO	with AFO		
good				
Nikamp 2017 (foll ow-up <3 months, early group)			0.27 (-0.42, 0.97)	15.08
Nikamp 2017 (follow-up <3 months, delayed group)			0.90 (0.13, 1.68)	12.11
Nikamp 2017 (follow-up 6-month, early group)			1.00 (0.23, 1.76)	12.55
Nikamp 2017 (follow-up 6-month, delayed group)			1.20 (0.40, 2.01)	11.28
Subtotal (I-squared = 13.4%, p = 0.325)		$\diamond$	0.81 (0.40, 1.22)	51.02
fair				
de Sèze 2011 (Chignon group, follow-up <3 months)			0.45 (-0.33, 1.23)	12.05
de Sèze 2011 (Chignon group, follow-up >3 months)	_		0.51 (-0.29, 1.31)	11.48
de Sèze 2011 (AFO-PLS group, follow-up <3 months)		-	0.36 (-0.36, 1.08)	14.04
de Sèze 2011 (AFO-PLS group, follow-up >3 months)	-		0.67 (-0.13, 1.47)	11.41
Subtotal (I-squared = 0.0%, p = 0.953)		$\Leftrightarrow$	0.49 (0.10, 0.88)	48.98
Overall (I-squared = 0.0%, p = 0.645)		$\diamond$	0.65 (0.38, 0.92)	100.00
NOTE: Weights are from random effects analysis				
-2.01		<b> </b> 0 2	<b> </b> 01	
-201				


**Supplemental Figure 7.** Funnel plot. Solid circles indicate the included studies. a) Berg Balance Scale, b) Timed Up and Go test, c) Functional Ambulation Categories. SMD: standardized mean difference.








**Supplemental Figure 8.** Egger's graphs show no potential publication bias for the outcomes (confidence interval crosses zero). Solid and open circles indicate the included studies. a) 6-Minute Walking Test, b) Timed Up-Stairs, c) Motricity Index.





Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Stroke phase	<6 months	7	0.765	0.251, 1.278	60.94	27.15	77.9%	0.000
-	> 6 months	4	0.211	-0.126, 0.547	39.06	4.64	35.3%	0.200
	mixed	-	-	-	-	-	-	-
Adaptation time	immediate	2	0.059	-0.214, 0.332	22.68	0.12	0.0%	0.724
	<3 months	6	0.479	0.069, 0.888	53.67	10.28	59.7%	0.029
	> 3 months	3	1.190	0.170, 2.211	23.66	12.42	80.5%	0.006
Quality	poor	2	0.115	-0.447, 0.677	17.43	1.36	26.5%	0.243
	fair	5	0.253	-0.092, 0.597	52.13	10.78	62.9%	0.029
	good	4	1.274	0.754, 1.794	30.44	4.92	39.1%	0.178
Walking speed	household	5	1.104	0.646, 1.561	41.71	8.52	53.0%	0.005
	Limited- community	4	0.076	-0.161, 0.313	40.10	1.55	0.0%	0.634
	community	1	-0.287	-0.989, 0.415	8.55	0.00	-	-

Supplemental table 1. Sub-group analysis between potential factors for Berg Balance Scale

SMD, Standardized Mean Difference

# Supplemental table 2. Sub-group analysis between potential factors for Timed Up and Go test

Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Stroke phase	<6 months	5	-0.348	-0.645, - 0.050	34.72	1.60	0.0%	0.809
	> 6 months	10	-0.501	-0.821, - 0.182	65.28	15.70	42.7%	0.073
	mixed	-	-	-	-	-	-	-
AFO type	non- articulared	8	-0.259	0.599 <i>,</i> 0.081	44.06	9.09	23.0%	0.246
	articulared	3	-0.736	-1.348, - -0.124	27.74	5.33	62.5%	0.070
	mixed	4	-0.592	-0.942 <i>,</i> - 0.243	28.20	0.58	0.0%	0.900
Adaptation time	immediate	3	-0.860	-1.359, - 0.360	15.39	0.41	0.0%	0.813
	<3 months	6	-0.305	-0.740, -	48.98	12.69	60.6%	0.026

				0.064				
	> 3 months	6	-0.466	-0.787, -	35.63	1.12	0.0%	0.953
				0.145				
Quality	poor	5	-0.766	-1.089, -	36.01	2.76	0.0%	0.737
				0.443				
	fair	6	-0.233	-0.490,	45.01	8.02	50.1%	0.091
				0.023				
	good	4	-0.437	-0.896,	18.98	1.35	0.0%	0.717
				0.022				
Walking	household	5	-0.433	-0.731, -	34.09	2.03	0.0%	0.729
speed				0.134				
	Limited-	9	-0.573	-0.821, -	58.81	5.71	0.0%	0.679
	community			0.326				
	community	1	0.661	-0.058,	7.10	0.00	-	-
				1.379				

SMD: Standardized Mean Difference, AFO: Ankle-Foot Orthosis

# Supplemental table 3. Sub-group analysis between potential factors for Functional Ambulation Categories

Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Stroke phase	<6 months	10	1.849	1.209, 2.490	69.27	46.54	80.7%	0.000
	> 6 months	2	1.581	0.878, 2.283	14.93	1.67	40.3%	0.196
	mixed	2	1.324	-0.053 <i>,</i> 2.701	15.81	8.84	88.7%	0.003
AFO type	non- articulared	9	1.870	1.128, 2.612	62.94	53.72	85.1%	0.000
	articulared	3	1.491	0.878, 2.103	22.13	3.63	44.9%	0.163
	mixed	2	1.548	0.878, 2.283	14.93	1.67	40.3%	0.196
Adaptation time	immediate	1	4.345	3.188, 5.501	5.97	0.00	-	-
	<3 months	8	1.328	0.857, 1.799	59.40	20.97	66.6%	0.004
	> 3 months	5	1.896	1.256, 2.536	34.64	10.27	61.0%	0.036
Quality	poor	3	1.198	0.334 <i>,</i> 2.062	22.47	7.76	74.2%	0.021
	fair	7	1.812	1.047, 2.577	49.92	36.14	83.4%	0.000
	good	4	1.999	1.170, 2.829	27.60	10.06	70.2%	0.018

SMD: Standardized Mean Difference, AFO: Ankle-Foot Orthosis

Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Stroke phase	<6 months	5	1.014	0.543, 1.486	74.92	7.28	45.0%	0.122
	> 6 months	2	0.564	-0.029, 1.157	25.66	0.43	0.0%	0.513
	mixed	-	-	-	-	-	-	-
Adaptation time	immediate	2	0.473	-0.160, 1.106	23.36	0.67	0.0%	0.412
	<3 months	2	0.880	0.350, 1.411	31.51	0.04	0.0%	0.845
	> 3 months	3	1.167	0.375, 1.958	45.13	6.11	67.3%	0.047
Quality	poor	3	0.469	0.011, 0.927	41.66	0.67	0.0%	0.714
	fair	-	-	-	-	-	-	-
	good	4	1.187	0.782 <i>,</i> 1.593	58.34	3.11	3.7%	0.374
Walking speed	household	5	0.995	0.654, 1.336	77.52		38.0%	0.168
	Limited- community	2	0.473	-0.160, 1.106	22.48		0.0%	0.412
	community	-	-	-	-		-	-

Supplemental table 4. Sub-group analysis between potential factors for 6-Minute Walking Test

SMD: Standardized Mean Difference,

# Supplemental table 5. Sub-group analysis between potential factors for Timed Up-Stairs

Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Stroke phase	<6 months	5	-0.383	-0.898, 0.132	57.59	6.56	39.1%	0.161
-	> 6 months	3	-0.410	-0.816, - 0.003	42.41	1.40	0.0%	0.497
	mixed	-	-	-	-	-	-	-
Adaptation time	immediate	1	-0.796	-1.568, - 0.024	12.22	0.00	-	-
	<3 months	3	-0.099	-0.447, 0.249	45.30	1.09	0.0%	0.580
	> 3 months	4	-0.470	-0.969, 0.028	42.48	4.08	26.4%	0.253
Quality	poor	-	-	-	-	-	-	-
	fair	4	-0.220	-0.507 <i>,</i> 0.068	74.81	3.09	2.9%	0.378
	good	4	-0.621	-1.245,	25.19	3.68	8.5%	0.298

				0.003				
Walking	household	6	-0.458	-0.912, -	69.81	8.34	40.0%	0.139
speed				0.005				
	Limited-	2	-0.262	-0.739,	30.19	0.07	0.0%	0.794
	community			0.216				
	community	-	-	-	-	-	-	-

SMD: Standardized Mean Difference,

# Supplemental table 6. Sub-group analysis between potential factors for Motricity Index

Subgroup variables	Categorized into	No. of trials	SMD	CI 95%	% Weight	Heterogeneity Chi <sup>2</sup>	I <sup>2</sup>	P-value
Adaptation	immediate	-	-	-	-	-	-	-
time	<3 months	4	0.479	0.109, 0.850	53.28	1.59	0.0%	0.661
	> 3 months	4	0.847	0.451, 1.243	1.243	1.76	0.0%	0.623
Quality	poor	-	-	-	-	-	-	-
	fair	4	0.489	0.103	0.876	0.34	0.0%	0.953
	good	4	0.812	0.405 <i>,</i> 1.219	51.02	3.47	13.4%	0.325
Walking	household	-	-	-	-	-	-	-
speed	Limited- community	-	-	-	-	-	-	-
	community	-	-	-	-	-	-	-

SMD: Standardized Mean Difference,

# Supplemental table 7. Assessment of publication bias

	No. of trials	Publication bias		
Analysis		Begg's test:	Egger's test:	
		z-test	Intercept	
		P-value	t-test	
			P-value	
Berg Balance	11	1.95	1.67	
Scale		0.052	0.130	
Timed Up and	15	-0.84	-0.64	
Go test		0.400	0.536	
Functional	14	3.12	4.29	
Ambulation		0.002	0.001	
Categories				
6-Minute	7	1.65	1.15	
Walking Test		0.099	0.302	
Timed Up-Stairs	8	-0.99	-1.84	
		0.322	0.116	
Motricity Index 8		1.73	2.05	
		0.083	0.087	

Supplemental table 8. The list of the studies identified for quantitative analysis by a meta-analysis with reference numbers

Author/ Year
Abe(2009) <sup>37</sup>
Assawapalangchai $(2017)^{38}$
Cakar(2010) <sup>28</sup>
De Sèze(2011) <sup>50</sup>
de Wit (2004) <sup>51</sup>
Doğan (2011) <sup>25</sup>
Erel (2011) <sup>46</sup>
Hale(2013) <sup>32</sup>
Hyun(2015) <sup>33</sup>
Maeda(2009) <sup>23</sup>
Nevisipour(2019) <sup>52</sup>
Nikamp(2017) <sup>47</sup>
Nikamp(2017) <sup>48</sup>
Pardo (2015) <sup>40</sup>
Pavlik (2008) <sup>39</sup>
Simons (2009) <sup>34</sup>
Sheffler(2006) <sup>29</sup>
Tomioka(2017) <sup>31</sup>
Tyson(2009) <sup>36</sup>
Tyson(2001) <sup>35</sup>
Wang(2005) <sup>43</sup>
Yue (2013) <sup>55</sup>